Anticancer treatments using radioactive PARP inhibitors
By using radiopharmaceutical compounds that target PARP enzymes, the problem of treating cancers expressing PARP enzymes that are difficult to treat in existing technologies has been solved, achieving highly efficient killing of cancer cells and imaging diagnosis.
Patent Information
- Application Number
- CN202380022012.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-15
- Filing Date
- 2023-02-15
- Publication Date
- 2024-11-01
AI Technical Summary
Current technologies are insufficient to effectively treat cancers that express PARP enzymes, such as pancreatic ductal adenocarcinoma and glioblastoma, necessitating new treatment methods.
A radiopharmaceutical compound targeting the PARP enzyme has been developed. By administering a therapeutically effective amount of the compound or its pharmaceutically acceptable salt, hydrate, or solvate, it acts directly on cancer cells expressing the PARP enzyme, releasing a lethal dose of radiation.
This compound can target and kill cancer cells expressing PARP enzymes, showing significant anti-cancer activity and imaging potential, and is particularly suitable for the treatment and diagnosis of refractory cancers.
Smart Images

Figure CN118891065A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a new anticancer radiopharmaceutical therapy. The anticancer therapy is particularly suitable for targeting cancers expressing the PARP enzyme. The new therapy involves compounds that are Auger-emitting radiopharmaceuticals that target PARP, and the present invention relates to these compounds, methods for preparing these compounds, their therapeutic use and / or their use as imaging agents. Background Art
[0002] Cancer is caused by altered cell proliferation and is characterized by increased genomic instability. Expression of the DNA damage repair enzyme PARP and closely related enzymes is increased in tumor tissues compared to surrounding normal tissues. The PARP enzyme binds to DNA through single-strand breaks, utilizes the substrate NAD+ and catalytically converts the latter to adenosine ribose adducts on target proteins. Compounds that bind to the PARP enzyme and hinder NAD+ binding can inhibit PARP and trap the enzyme to DNA.
[0003] There remains a need for new and effective cancer treatments. In particular, new and effective treatments are needed for difficult-to-treat cancers such as pancreatic ductal adenocarcinoma and glioblastoma, a large proportion of which express the PARP enzyme.
[0004] The present invention has been designed in view of the foregoing. Summary of the invention
[0005] According to a first aspect of the present invention there is provided a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
[0006] According to another aspect of the present invention, there is provided a pharmaceutical composition comprising a compound as defined herein or a pharmaceutically acceptable salt, hydrate or solvate thereof, and a pharmaceutically acceptable diluent or carrier.
[0007] According to another aspect of the present invention, there is provided a method of treating cancer in a patient in need of such treatment, the method comprising administering to the patient a therapeutically effective amount of a compound as defined herein or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.
[0008] According to another aspect of the present invention, there is provided a method for treating cancer in which PARP enzyme expression is involved in a patient in need of such treatment, the method comprising administering to the patient a therapeutically effective amount of a compound as defined herein or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.
[0009] According to another aspect of the present invention there is provided a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition, for use in therapy.
[0010] According to another aspect of the present invention there is provided a compound as defined herein or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition for use as a medicament.
[0011] According to another aspect of the present invention, there is provided a compound as defined herein or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition for use in treating cancer.
[0012] According to another aspect of the present invention, there is provided a compound as defined herein or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition for use in treating cancer involving expression of the PARP enzyme.
[0013] According to another aspect of the present invention, there is provided use of a compound as defined herein or a pharmaceutically acceptable salt, hydrate or solvate thereof in the preparation of a medicament for treating cancer.
[0014] According to another aspect of the present invention, there is provided use of a compound as defined herein or a pharmaceutically acceptable salt, hydrate or solvate thereof in the preparation of a medicament for treating cancer involving expression of the PARP enzyme.
[0015] According to another aspect of the present invention, there is provided a process for preparing a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
[0016] According to another aspect of the present invention, there is provided a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof, which can be obtained by a method for preparing a compound as defined herein, or obtained by a method for preparing a compound as defined herein, or directly obtained by a method for preparing a compound as defined herein.
[0017] According to another aspect of the present invention, there is provided a novel intermediate as defined herein, which is suitable for use in any one of the synthetic methods listed herein.
[0018] Features relating to one aspect of the invention, including optional, suitable and preferred features, may also be features relating to any other aspect of the invention, including optional, suitable and preferred features. DETAILED DESCRIPTION
[0019] definition
[0020] Unless otherwise stated, the following terms used in the specification and claims have the following meanings.
[0021] It should be understood that references to "treating" or "treating" include prevention as well as alleviation of established symptoms of a condition. Thus, "treating" or "treating" a state, disorder, or condition includes: (1) preventing or delaying the onset of clinical symptoms of the state, disorder, or condition that develops in a person who may be suffering from or susceptible to the state, disorder, or condition but does not yet experience or show clinical or subclinical symptoms of the state, disorder, or condition, (2) inhibiting the state, disorder, or condition, i.e., arresting, reducing, or delaying the development of the disease or its recurrence (in the case of maintenance treatment) or at least one clinical or subclinical symptom thereof, or (3) relieving or ameliorating the disease, i.e., causing regression of the state, disorder, or condition or at least one clinical or subclinical symptom thereof.
[0022] "PARP" or "PARP enzyme" referred to herein refers to all isoforms of the PARP enzyme, including isoforms PARP1 to PARP17.
[0023] "Therapeutically effective amount" refers to the amount of a compound that is sufficient to achieve treatment of a disease when administered to a mammal to treat the disease. "Therapeutically effective amount" will vary depending on the compound, its molar activity, the disease and its severity, and the age, weight, etc. of the mammal being treated. It should be understood that, for example, in humans or other mammals, the therapeutically effective amount can be determined experimentally in a laboratory or clinical setting, or the therapeutically effective amount can be the amount required by the guidelines of the U.S. Food and Drug Administration (FDA) or equivalent foreign regulatory agencies for a specific disease and the subject being treated. It should be understood that determining a suitable dosage form, dosage, and route of administration is within the ordinary skill level of the pharmaceutical and medical fields.
[0024] "Subject" and "patient" used alone or in combination with one or more other terms herein refer to animals (e.g., mammals), especially humans. Suitably, "subject" and "patient" can be non-human animals (e.g., livestock and domestic pets) or humans.
[0025] As used herein, alone or in combination with another term or terms, "pharmaceutically acceptable" refers to a material that is generally chemically and / or physically compatible with the other ingredients (e.g., with respect to a formulation), and / or is generally physiologically compatible with a recipient thereof (e.g., a subject).
[0026] In this specification, the term "alkyl" includes straight-chain and branched alkyl groups. When a single alkyl group such as "propyl" is mentioned, only the straight-chain form is referred to, and when a single branched alkyl group such as "isopropyl" is mentioned, only the branched form is referred to. For example, "(1-6C)alkyl" includes (1-4C)alkyl, (1-3C)alkyl, propyl, isopropyl and tert-butyl.
[0027] The term "(m-nC)" or "(m-nC) group" used alone or as a prefix refers to any group having from m to n carbon atoms.
[0028] "Alkylene" is an alkyl group that is located between two other chemical groups and serves to connect them. Thus, "(1-6C)alkylene" refers to a straight-chain saturated divalent hydrocarbon group of 1 to 6 carbon atoms or a branched saturated divalent hydrocarbon group of 3 to 6 carbon atoms, such as methylene (-CH2-), ethylene isomers (-CH(CH3)- and -CH2CH2-), propylene isomers (-CH(CH3)CH2-, -CH(CH2CH3)-, -C(CH3)2-, and -CH2CH2CH2-), pentylene (-CH2CH2CH2CH2CH2-), etc.
[0029] The term "alkenyl" refers to straight and branched chain alkyl groups containing 2 or more carbon atoms, wherein at least one carbon-carbon double bond is present in the group. Examples of alkenyl groups include ethenyl, propenyl, and but-2,3-enyl, and include all possible geometric (E / Z) isomers.
[0030] The term "alkynyl" refers to straight and branched chain alkyl groups containing 2 or more carbon atoms, wherein at least one carbon-carbon triple bond is present in the group. Examples of alkynyl groups include ethynyl and propynyl.
[0031] "(m-nC)cycloalkyl" refers to a saturated hydrocarbon ring system containing m to n carbon atoms. Exemplary cycloalkyl groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and bicyclo[2.2.1]heptyl.
[0032] The term "alkoxy" refers to O-linked straight and branched chain alkyl groups. Examples of alkoxy groups include methoxy, ethoxy and tert-butoxy.
[0033] As used herein, the term "haloalkyl" refers to an alkyl group in which one or more hydrogen atoms are replaced by a halogen (eg, fluorine) atom. Examples of haloalkyl groups include -CH2F, -CHF2, and -CF3.
[0034] The term "halogen" refers to fluorine, chlorine, bromine, iodine and astatine, suitably fluorine, chlorine, bromine and iodine, more suitably fluorine, chlorine and iodine.
[0035] The term "carbocyclyl", "carbocyclic" or "carbocycle" refers to a non-aromatic saturated or partially saturated monocyclic, fused, bridged or spirocyclic bicyclic carbon-containing ring system. The monocyclic carbocycle contains about 3 to 12 (suitably 3 to 7) ring atoms. The bicyclic carbocycle contains 6 to 17 member atoms in the ring, suitably 7 to 12 member atoms. The bicyclic carbocycle can be a fused ring, spiro ring or bridged ring system. Examples of carbocyclic groups include cyclopropyl, cyclobutyl, cyclohexyl, cyclohexenyl and spiro[3.3]heptyl.
[0036] The term "heterocyclyl", "heterocyclic" or "heterocycle" refers to a non-aromatic saturated or partially saturated monocyclic, fused, bridged or spiro bicyclic heterocyclic ring system. The monocyclic heterocyclic ring contains about 3 to 12 (suitably 3 to 7) ring atoms, with 1 to 5 (suitably 1, 2 or 3) heteroatoms selected from nitrogen, oxygen or sulfur in the ring. The bicyclic heterocyclic ring contains 7 to 17 member atoms in the ring, and 7 to 12 member atoms are suitable. The bicyclic heterocyclic ring can be a fused ring, a spiro ring or a bridged ring system. Examples of heterocyclic groups include cyclic ethers, such as oxirane, oxetane, tetrahydrofuran, dioxane and substituted cyclic ethers. Nitrogen-containing heterocyclic rings include, for example, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydrotriazinyl, tetrahydropyrazolyl, etc. Typical sulfur-containing heterocycles include tetrahydrothiophene, dihydro-1,3-dithiol, tetrahydro 2H-thiopyran and hexahydrothiophene. Other heterocycles include dihydrothiothio, tetrahydrooxazolyl, tetrahydrooxadiazolyl, tetrahydrooxazolyl, tetrahydrooxathiazolyl, hexahydrotriazinyl, tetrahydrooxazinyl, morpholinyl, thiomorpholinyl, tetrahydropyrimidinyl, dioxolane, octahydrobenzofuranyl, octahydrobenzimidazolyl and octahydrobenzothiazolyl. For sulfur-containing heterocycles, oxidized sulfur heterocycles containing SO or SO2 groups are also included. Examples include sulfoxide and sulfone forms of tetrahydrothiophene and thiomorpholinyl, such as tetrahydrothiophene 1,1-dioxide and thiomorpholinyl 1,1-dioxide. The heterocycle may contain 1 or 2 oxo (=O) or thio (=S) substituents. Suitable values for heterocyclic groups with 1 or 2 oxo (=O) or thio (=S) substituents are, for example, 2-oxopyrrolidinyl, 2-thiopyrrolidinyl, 2-oxoimidazolidinyl, 2-thioimidazolidinyl, 2-oxopiperidinyl, 2,5-dioxopyrrolidinyl, 2,5-dioxoimidazolidinyl or 2,6-dioxopiperidinyl. Specific heterocyclic groups are saturated monocyclic 3-7 membered heterocyclic groups containing 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur, such as azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, morpholinyl, tetrahydrothienyl, tetrahydrothienyl 1,1-dioxide, thiomorpholinyl, thiomorpholinyl 1,1-dioxide, piperidinyl, homopiperidinyl, piperazinyl or homopiperazinyl. As will be appreciated by the skilled artisan, any heterocyclic ring may be attached to another group via any suitable atom, such as via a carbon or nitrogen atom. However, references to piperidinyl or morpholino herein refer to the piperidin-1-yl or morpholin-4-yl ring attached through the ring nitrogen.
[0037] "Bridged ring system" refers to a ring system in which two rings share two or more atoms, see, e.g., Jerry March, Advanced Organic Chemistry, 4th edition, Wiley Interscience, pp. 131-133, 1992. Examples of bridged heterocyclyl ring systems include azabicyclo[2.2.1]heptane, 2-oxa-5-azabicyclo[2.2.1]heptane, azabicyclo[2.2.2]octane, azabicyclo[3.2.1]octane and quinuclidine.
[0038] "Spirocyclic bicyclic ring system" means that the two ring systems share a common spirocyclic carbon atom, i.e., the heterocyclic ring is connected to another carbocyclic ring or heterocyclic ring through a common spirocyclic carbon atom. Examples of spirocyclic ring systems include 6-azaspiro[3.4]octane, 2-oxa-6-azaspiro[3.4]octane, 2-azaspiro[3.3]heptane, 2-oxa-6-azaspiro[3.3]heptane, 7-oxa-2-azaspiro[3.5]nonane, 6-oxa-2-azaspiro[3.4]octane, 2-oxa-7-azaspiro[3.5]nonane and 2-oxa-6-azaspiro[3.5]nonane.
[0039] As used herein, "aromatic" alone or in combination with another term or terms, refers to monocyclic and polycyclic ring systems containing 4n+2π electrons, where n is an integer. Aromatic is understood to refer to and include ring systems containing only carbon atoms (i.e., "aryl") as well as ring systems containing at least one heteroatom selected from N, O or S (i.e., "heteroaromatic" or "heteroaryl"). Aromatic ring systems may be substituted or unsubstituted.
[0040] As used herein, "non-aromatic" alone or in combination with another term or terms, refers to a monocyclic or polycyclic ring system having at least one double bond that is not part of an extended conjugated π system. As used herein, non-aromatic refers to and includes ring systems containing only carbon atoms as well as ring systems containing at least one heteroatom selected from N, O or S. Non-aromatic ring systems may be substituted or unsubstituted.
[0041] The term "heteroaryl" or "heteroaromatic" refers to an aromatic monocyclic, bicyclic or polycyclic ring containing one or more (e.g., 14, particularly 1, 2 or 3) heteroatoms selected from nitrogen, oxygen or sulfur. The term heteroaryl includes monovalent and divalent substances. Examples of heteroaryls are monocyclic and bicyclic groups containing 5-12 ring members, more typically 5-10 ring members. Heteroaryls can be, for example, 5 or 6-membered monocyclic or 9 or 10-membered bicyclic rings, such as bicyclic structures formed by fused 5 and 6-membered rings or two fused 6-membered rings. Each ring can contain up to about 4 heteroatoms typically selected from nitrogen, sulfur and oxygen. Typically, the heteroaryl ring will contain up to 3 heteroatoms, more typically up to 2, such as a single heteroatom. In one embodiment, the heteroaryl ring contains at least one ring nitrogen atom. The nitrogen atom in the heteroaryl ring can be basic, such as in the case of imidazole or pyridine, or substantially non-basic, such as in the case of indole or pyrrole nitrogen. Generally, the number of basic nitrogen atoms present in a heteroaryl group, including any amino substituents on the ring, will be less than five.
[0042] Examples of heteroaryl groups include furanyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazolyl, benzofuranyl, indolyl, isoindolyl, benzothienyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, indazolyl, purinyl, benzofurazanyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, cinnolinyl, [1,2-b][1,2,4]triazinyl. "Heteroaryl" also includes partially aromatic bicyclic or polycyclic ring systems in which at least one ring is aromatic and one or more other rings are non-aromatic, saturated or partially saturated rings, provided that at least one ring contains one or more heteroatoms selected from nitrogen, oxygen or sulfur. Examples of some aromatic heteroaryl groups include, for example, tetrahydroisoquinolyl, tetrahydroquinolyl, 2-oxo-1,2,3,4-tetrahydroquinolyl, dihydrobenzothienyl, dihydrobenzofuranyl, 2,3-dihydrobenzo[1,4]dioxy, benzo[1,3]dioxolyl, 2,2-dioxo-1,3-dihydro-2-benzothienyl, 4,5,6,7-tetrahydrobenzofuranyl, indolyl, 1,2,3,4-tetrahydro-1,8-naphthyridinyl, 1,2,3,4-tetrahydropyrido[2,3-b]pyrazinyl, and 3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazinyl.
[0043] Examples of five-membered heteroaryl groups include, but are not limited to, pyrrolyl, furanyl, thienyl, imidazolyl, furazanyl, oxazolyl, oxadiazolyl, oxatriazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, and tetrazolyl.
[0044] Examples of six-membered heteroaryl groups include, but are not limited to, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, and triazinyl.
[0045] The bicyclic heteroaryl group may be, for example, a group selected from:
[0046] a benzene ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms;
[0047] a pyridine ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms;
[0048] a pyrimidine ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;
[0049] a pyrrole ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms;
[0050] a pyrazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;
[0051] a pyrazine ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;
[0052] an imidazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;
[0053] an oxazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;
[0054] an isoxazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;
[0055] a thiazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;
[0056] an isothiazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;
[0057] a thiophene ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms;
[0058] a furan ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms;
[0059] a cyclohexyl ring fused to a 5- or 6-membered heteroaromatic ring containing 1, 2 or 3 ring heteroatoms; and
[0060] A cyclopentyl ring fused to a 5- or 6-membered heteroaromatic ring containing 1, 2 or 3 ring heteroatoms.
[0061] Specific examples of bicyclic heteroaryl groups containing a six-membered ring fused to a five-membered ring include, but are not limited to, benzofuranyl, benzothiophenyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, isobenzofuranyl, indolyl, isoindolyl, indolizinyl, indolyl, isoindolyl, purinyl (e.g., adeninyl, guanidinyl), indazolyl, benzodioxolyl, and pyrazolopyridinyl.
[0062] Specific examples of bicyclic heteroaryl groups containing two fused six-membered rings include, but are not limited to, quinolinyl, isoquinolinyl, chromanyl, thiochromanyl, chromenyl, isochromenyl, chromanyl, isochromanyl, benzodioxanyl, quinolinyl, benzoxazinyl, benzodiazinyl, pyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, naphthyridinyl, and pteridinyl.
[0063] The term "aryl" refers to a cyclic or polycyclic aromatic ring having 5 to 12 carbon atoms. The term aryl includes monovalent and divalent species. Examples of aryl include, but are not limited to, phenyl, biphenyl, naphthyl, etc. In a specific embodiment, aryl is phenyl.
[0064] The specification also uses multiple compound terms to describe groups containing more than one functionality. For example, (3-6C)cycloalkyl(m-nC)alkyl includes (m-nC)alkyl substituted with (3-6C)cycloalkyl.
[0065] The term "optionally substituted" refers to both substituted and unsubstituted groups, structures or molecules. 1 One or any CH, CH2, CH3 group or heteroatom (i.e. NH) in the group is optionally substituted" suitably means R 1 (Any) hydrogen radical in a group is replaced by the relevant specified group.
[0066] When the optional substituents are selected from "one or more" groups, it is understood that the definition includes all substituents selected from one specific group or substituents selected from two or more specific groups. In some embodiments, one or more refers to one, two or three. In another embodiment, one or more refers to one or two. In a specific embodiment, one or more refers to one.
[0067] The phrase "compounds of the invention" refers to those compounds disclosed herein, both those described in a generic manner and those specifically enumerated.
[0068] When "about" is used herein in connection with a measurable value, such as an amount or a period of time, it is intended to include reasonable variations from that value, for example, to take into account experimental error in measuring the value.
[0069] Compound
[0070] In one aspect, the present invention relates to a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof having structural formula (I), as shown below:
[0071]
[0072] in:
[0073] A1 and A2 are independently selected from CR1 and CH, CR1 and CF, CR1 and N, CH and CR1, CF and CR1 or NH and CR1;
[0074] R1 is a radioactive isotope of iodine (I) or astatine (At);
[0075] A3 is selected from N-X1-R3 or C(R4)OR5;
[0076] X1 is absent or selected from -C(O)-, -[CH2] 1-3 -, -C(O)NH-, -C(O)O- or -S(O) 0-2 -;
[0077] R3 is H, (1-10C) alkyl, (3-8C) cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein each alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally replaced by one or more R A Substituent substitution;
[0078] R4 is selected from H or C 1-4 Alkyl; and
[0079] R5 is selected from (1-7C) alkyl, heterocyclic and aryl, which groups are optionally replaced by one or more R A or R4 and R5 together with the carbon atom and oxygen atom to which they are attached form a spirocyclic -C 5-7 Oxygen-containing heterocyclic group, which is optionally substituted by one or more R A Substituents are substituted or fused to the phenyl or 5- or 6-membered heteroaryl ring; and each R A The substituents are independently selected from fluorine, cyano, (1-4C) alkyl, (1-4C) haloalkyl, (1-4C) hydroxyalkyl, phenyl, 4- to 6-membered heterocyclyl, 5- to 6-membered heteroaryl, -OR 1a 、-NR 1a R 1b 、-C(O)R 1a 、-C(O)N(R 1b )R 1a 、N(R 1b )C(O)R 1a 、-S(O) p R 1a (where p is 0, 1 or 2), -SO2N(R1b )R 1a 、-N(R 1b )SO2R 1a , where R 1a and R 1b Each is independently selected from hydrogen, (1-4C)alkyl or (3-6C)alkyl.
[0080] Specific compounds of the present invention include, for example, compounds of formula (I) as defined herein, or pharmaceutically acceptable salts, hydrates and / or solvates thereof, which have one of the structural formulae Ia to Ij shown below:
[0081]
[0082]
[0083]
[0084] wherein, as the case may be, R1, R3 and R5 are each as defined herein.
[0085] Specific compounds of the present invention include, for example, compounds of formula (I) [including sub-formulas Ia to Ii], or pharmaceutically acceptable salts, hydrates and / or solvates thereof, wherein, unless otherwise specified, A1, A2, A3, R1, X1, R3, R4, R5 and R A Each has the meaning defined in any of paragraphs (1) to (34) above or below:
[0086] (1) A1 and A2 are independently selected from CR1 and CH, CR1 and CF, CH and CR1 or CF and CR1;
[0087] (2) A1 and A2 are independently selected from CR1 and CH, CR1 and N, CH and CR1 or NH and CR1;
[0088] (3) A1 and A2 are independently selected from CR1 and CH, CH and CR1 or CF and CR1;
[0089] (4) A1 is CR1, and A2 is CH;
[0090] (5) R1 is a radioactive isotope of iodine (I);
[0091] (6) R1 is a radioactive isotope of astatine (At);
[0092] (7) R1 is selected from 123 I. 131 I. 127 I. 124 I or 211 At, or 123 I.131 I. 124 I or 211 At
[0093] (8) R1 is selected from 123 I. 131 I or 211 At;
[0094] (9) R1 is 123 I or 131 I
[0095] (10) R1 is 123 I;
[0096] (11) A3 is N-X1-R3;
[0097] (12) A3 is C(R4)OR5;
[0098] (13) X1 is absent or selected from -C(O)-, -[CH2] 1-3 - or -C(O)NH-;
[0099] (14) X1 is -C(O)-;
[0100] (15) R3 is H, (1-6C)alkyl, (3-8C)cycloalkyl, phenyl, 4- to 10-membered heterocyclyl, or 5- or 6-membered heteroaryl, wherein each alkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl is optionally substituted with one or more R A Substituent substitution;
[0101] (16) R3 is H, (1-6C)alkyl, (3-8C)cycloalkyl, phenyl, 4- to 8-membered heterocyclyl, or 5- or 6-membered heteroaryl, wherein each alkyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl is optionally substituted with one or more R A Substituent substitution;
[0102] (17) R3 is (1-6C)alkyl or (3-8C)cycloalkyl, each of which is optionally substituted with one or more R A Substituent substitution;
[0103] (18) R3 is (3-8C)cycloalkyl, which is optionally substituted with one or more R A Substituent substitution;
[0104] (19) R3 is (3-6C)cycloalkyl, which is optionally substituted with one or more R A Substituent substitution;
[0105] (20) R3 is cyclopropyl;
[0106] (21) R4 is selected from H or C 1-4 alkyl;
[0107] (22) R4 is selected from H or methyl;
[0108] (23) R4 is H;
[0109] (24) R5 is selected from (1-7C) alkyl, (3-8C) cycloalkyl, 4- to 10-membered heterocyclic group and phenyl, which groups are optionally replaced by one or more R A Substituent substitution;
[0110] (25) R5 is selected from (1-7C)alkyl, 4- to 10-membered heterocyclic group and phenyl, which groups are optionally replaced by one or more R A Substituent substitution;
[0111] (26) R5 is selected from (1-7C) alkyl, (3-6C) cycloalkyl, 4- to 10-membered heterocyclic group and phenyl, which groups are optionally replaced by one or more R A Substituent substitution;
[0112] (27) R5 is (1-6C)alkyl, which is optionally substituted with one or more R A Substituent substitution;
[0113] (28)R 5 It is methyl;
[0114] (29) R4 and R5 together with the carbon atom and oxygen atom to which they are attached form a spirocyclic -C 5-6 Oxygen-containing heterocyclic group,
[0115] It is optionally replaced by one or more R A The substituent is substituted or fused to the phenyl or 5- or 6-membered heteroaryl ring; (30) R4 and R5 together with the carbon atom and oxygen atom to which they are attached form a spiro-C 5-6 Oxygen-containing heterocyclic group; (31) each R A The substituents are independently selected from fluorine, cyano, (1-4C) alkyl, (1-4C) haloalkyl, (1-4C) hydroxyalkyl, -OR 1a 、-NR 1a R 1b 、-C(O)R 1a 、-C(O)N(R 1b )R 1a 、N(R 1b )C(O)R 1a 、-
[0116] S(O) p R 1a (where p is 0, 1 or 2), -SO2N(R 1b )R 1a 、-N(R 1b )SO2R1a , where R 1a and R 1b Each is independently selected from hydrogen or (1-4C)alkyl.
[0117] (32) Each R A The substituents are independently selected from fluorine, cyano, (1-4C) alkyl, (1-4C) haloalkyl, (1-4C) hydroxyalkyl, -OR 1a 、-NR 1a R 1b 、-C(O)R 1a 、-C(O)N(R 1b )R 1a 、N(R 1b )C(O)R 1a 、-
[0118] S(O) p R 1a (where p is 0, 1 or 2), where R 1a and R 1b are each independently selected from hydrogen or (1-2C)alkyl;
[0119] (33) Each R A The substituents are independently selected from fluorine, cyano, (1-4C)alkyl, (1-4C)haloalkyl, (1-4C)hydroxyalkyl or -OR 1a , where R 1a is selected from hydrogen or (1-2C)alkyl;
[0120] (34) Each R A The substituent is fluorine.
[0121] Suitably, A1 and A2 are as defined in any of the above numbered paragraphs (1) to (4). More suitably, A1 and A2 are as defined in the above numbered paragraphs (3) or (4). Most suitably, A1 and A2 are as defined in the above numbered paragraph (4).
[0122] Suitably, R1 is as defined in any of the above numbered paragraphs (5) to (10). More suitably, R1 is as defined in any of the above numbered paragraphs (7) to (10). Most suitably, R1 is as defined in the above numbered paragraph (10).
[0123] Suitably, A3 is as defined in paragraph (11) above.
[0124] Suitably, X1 is as defined in paragraph (13) or (14) above. Most suitably, X1 is as defined in numbered paragraph (14) above.
[0125] Suitably, R3 is as defined in any of the above numbered paragraphs (15) to (20). More suitably, R3 is as defined in any of the above numbered paragraphs (18) to (20). Most suitably, R3 is as defined in the above numbered paragraph (20).
[0126] Suitably, R4 is as defined in any of the numbered paragraphs (21) to (23) above. More suitably, R4 is as defined in the numbered paragraphs (22) or (23). Most suitably, R4 is as defined in the numbered paragraph (23) above.
[0127] Suitably, R5 is as defined in any of the numbered paragraphs (24) to (28) above. More suitably, R5 is as defined in any of the numbered paragraphs (26) to (28). Most suitably, R5 is as defined in the numbered paragraph (28) above.
[0128] Suitably, if R4 and R5 are both linked, they are as defined in paragraph (29) or (30) above.
[0129] Suitably, R A As defined in any of the above numbered paragraphs (31) to (34). More suitably, R A As defined in numbered paragraph (33) or (34) above. Most suitably, R A As defined in numbered paragraph (34) above.
[0130] Suitably, R5 is as defined in any of the above numbered paragraphs (28) to (30). More suitably, R5 is as defined in the above numbered paragraphs (29) or (30). Most suitably, R5 is as defined in the above numbered paragraph (30).
[0131] Suitably, y is as defined in numbered paragraph (36) above.
[0132] Suitably, x is as defined in numbered paragraph (40) above.
[0133] As described above, specific compounds of the present invention include, for example, compounds of formula (I) or pharmaceutically acceptable salts, hydrates and / or solvates thereof, which are defined as having one of the structural formulas Ia to Ij as shown above, wherein R1, R3 and R5 each have any of the definitions given herein, as the case may be.
[0134] Specific compounds of the present invention have the structural formulas Ij and Ik shown below:
[0135]
[0136] (Also referred to herein as CC1 (4-[(3-[(4-cyclopropylcarbonyl)piperazin-1-yl]carbonyl-4-iodophenyl]methyl (2H)phthalazin-1-one)
[0137]
[0138] or a pharmaceutically acceptable salt, hydrate and / or solvate thereof.
[0139] Specific compounds of the present invention have the above structural formula Ij, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof.
[0140] The various functional groups and substituents constituting the compounds of formula (I) or subformulae (Ia) to (Ie) are generally selected so that the molecular weight of the compounds of formula (I) does not exceed 1000.
[0141] Suitable pharmaceutically acceptable salts of the compounds of the invention are, for example, acid addition salts of the compounds of the invention having sufficient basicity, for example, with, for example, inorganic or organic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, trifluoroacetic acid, formic acid, citric acid methanesulfonic acid or maleic acid. In addition, suitable pharmaceutically acceptable salts of the compounds of the invention having sufficient acidity are alkali metal salts, such as sodium or potassium salts, alkaline earth metal salts, such as calcium or magnesium salts, ammonium salts or salts formed with organic bases providing pharmaceutically acceptable cations, such as salts formed with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
[0142] Compounds that have the same molecular formula but differ in the nature or order of bonding of their atoms or the arrangement of atoms in space are called "isomers". Compounds that differ in the arrangement of atoms in space are called "stereoisomers". Stereoisomers that are not mirror images of each other are called "diastereomers", while those that are not superimposable mirror images of each other are called "enantiomers". When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers may exist. Enantiomers can be characterized by the absolute configuration of their asymmetric center and described by the R- and S-sequence rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and is designated as right- or left-handed (i.e., as (+) or (-)-isomers, respectively). Chiral compounds can exist as individual enantiomers or as mixtures thereof. Compounds containing equal proportions of enantiomers are called "racemic compounds".
[0143] The compounds of the present invention may have one or more asymmetric centers; thus, such compounds may be produced as individual (R) or (S) stereoisomers or mixtures thereof. Unless otherwise indicated, the description or naming of a particular compound in the specification and claims is intended to include its individual enantiomers and mixtures thereof, racemic or otherwise. Methods for determining stereochemistry and separating stereoisomers are well known in the art (see discussion in Chapter 4 of "Advanced Organic Chemistry", 4th edition J. March, John Wiley and Sons, New York, 2001), for example by synthesis from optically active starting materials or by resolution of racemic forms. Some compounds of the present invention may have geometric isomeric centers (E and Z isomers).
[0144] It is to be understood that the present invention includes all optical, diastereoisomers and geometric isomers and mixtures thereof which possess anti-cancer activity or are suitable as imaging agents.
[0145] The present invention also includes compounds of the present invention as defined herein, which contain one or more isotopic substitutions. For example, H may be in any isotopic form, including 1 H. 2 H(D) and 3 H(T); C can be in any isotopic form, including 12 C. 13 C and 14 C; and O can be in any isotopic form, including 16 O and 18 O; etc.
[0146] It will also be appreciated that certain compounds of formula (I) or subformulas Ia to Ik may exist in solvated and unsolvated forms, such as hydrated forms. It will be appreciated that the present invention encompasses all such active solvated forms.
[0147] It will also be appreciated that certain compounds of formula (I) or subformulas Ia to Ik may exhibit polymorphism and that the present invention encompasses all such active forms.
[0148] The compound of formula (I) or subformula Ia to Ik can exist with many different tautomeric forms, and when mentioning the compound of formula (I) or subformula Ia to Ik, all these forms are included. In order to avoid doubt, when the compound can exist with one of several tautomeric forms, and only specifically describe or show one, all others are included in formula (I) or subformula (Ia) to (Ie). The example of tautomeric form includes keto-, enol- and enolate-forms, for example the following tautomer pairs: keto / enol (as shown below), imines / enamines, amides / imino alcohols, amidines / amidines, nitroso-group / oximes, thioketones / enethiol and nitro / acidic nitro.
[0149]
[0150] Compounds of formula (I) or subformulas Ia to Ik containing amine functional groups can also form N-oxides. Compounds of formula (I) or subformulas Ia to Ik containing amine functional groups mentioned herein also include N-oxides. When the compound contains several amine functional groups, one or more nitrogen atoms can be oxidized to form N-oxides. Specific examples of N-oxides are N-oxides of nitrogen atoms of tertiary amines or nitrogen-containing heterocycles. N-oxides can be formed by treating the corresponding amine with an oxidant such as hydrogen peroxide or a peracid (e.g., peroxycarboxylic acid), see, for example, Jerry March's "Advanced Organic Chemistry", 4th edition, Wiley Interscience, pages. More specifically, N-oxides can be prepared by the procedure of LW Deady (Syn. Comm. 1977, 7, 509-514), wherein an amine compound is reacted with meta-chloroperbenzoic acid (mCPBA) in, for example, an inert solvent such as dichloromethane.
[0151] The compound of formula (I) or subformula Ia to Ik can be administered in the form of a prodrug, which decomposes in the human or animal body to release the compound of the present invention. Prodrugs can be used to change the physical properties and / or pharmacokinetic properties of the compounds of the present invention. When the compound of the present invention contains a suitable group or substituent, a prodrug can be formed, and the modified group can be connected to the group or substituent. Examples of prodrugs include ester derivatives that can be formed in vivo at the carboxyl or hydroxyl groups of the compounds of formula (I) or subformula Ia to Ik, and amide derivatives that can be formed in vivo at the carboxyl or amino groups of the compounds of formula (I) or subformula Ia to Ik.
[0152] Therefore, the present invention includes those compounds of formula (I) or subformulas Ia to Ik as defined above, when obtained by organic synthesis, and when obtained in the human or animal body by cleavage of their prodrugs. Therefore, the present invention includes those compounds of formula (I) or subformulas Ia to Ik produced by organic synthesis methods, and such compounds produced in the human or animal body by metabolism of precursor compounds, i.e. compounds of formula (I) or subformulas Ia to Ik, which may be synthetically produced compounds or metabolically produced compounds.
[0153] Suitable pharmaceutically acceptable prodrugs of the compounds of formula (I) or subformulas Ia to Ik are drugs which, based on sound medical judgment, are suitable for administration to the human or animal body without undesired pharmacological activity and undue toxicity.
[0154] Various forms of prodrugs have been described, for example in the following documents:-
[0155] a)Methods in Enzymology,Vol.42,p.309-396,edited by K.Widder,et al.(Academic Press,1985);
[0156] b)Design of Pro-drugs,edited by H.Bundgaard,(Elsevier,1985);
[0157] c)A Textbook of Drug Design and Development,edited by Krogsgaard-Larsen and H.Bundgaard,Chapter 5“Design and Application of Pro-drugs”,byH.Bundgaard p.113-191(1991);
[0158] d)H.Bundgaard,Advanced Drug Delivery Reviews,8,1-38(1992);
[0159] e)H.Bundgaard,et al.,Journal of Pharmaceutical Sciences,77,285(1988);
[0160] f)N.Kakeya,et al.,Chem.Pharm.Bull.,32,692(1984);
[0161] g)T.Higuchi and V.Stella,“Pro-Drugs as Novel Delivery Systems”,A.C.S.Symposium Series,Volume 14;and
[0162] h)E.Roche(editor),“Bioreversible Carriers in Drug Design”,PergamonPress,1987.
[0163] Suitable pharmaceutically acceptable prodrugs of compounds of formula (I) or subformulas Ia to Ik having a carboxyl group are, for example, esters thereof which can be cleaved in vivo. An in vivo cleavable ester of a compound of formula (I) or subformulas Ia to Ik containing a carboxyl group is, for example, a pharmaceutically acceptable ester which is cleaved in the human or animal body to produce the parent acid or parent alcohol. Pharmaceutically acceptable esters suitable for the carboxyl group include (1-6C)alkyl esters such as methyl, ethyl and tert-butyl esters, (1-6C)alkoxymethyl esters such as methoxymethyl ester, (1-6C)alkanoyloxymethyl esters such as pivaloyloxymethyl ester, 3-phthaloyl ester, (3-8C)cycloalkylcarbonyloxy-(1-6C)alkyl esters such as cyclopentylcarbonyloxymethyl ester and 1-cyclohexylcarbonyloxyethyl ester, 2-oxo-1,3-dioxymethyl esters such as 5-methyl-2-oxo-1,3-dioxol-4-ylmethyl ester and (1-6C)alkoxycarbonyloxy-(1-6C)alkyl esters such as methoxycarbonyloxymethyl ester and 1-methoxycarbonyloxyethyl ester.
[0164] Suitable pharmaceutically acceptable prodrugs of compounds of formula (I) or subformulas Ia to Ik with hydroxyl groups are, for example, esters or ethers that can be cleaved in vivo. Ester or ether that can be cleaved in vivo of compounds of formula (I) or subformulas Ia to Ik containing hydroxyl groups are, for example, pharmaceutically acceptable esters or ethers that are cleaved in vivo to produce parent hydroxyl compounds in human or animal bodies. Suitable pharmaceutically acceptable ester-forming groups of hydroxyl groups include inorganic esters, such as phosphates (including phosphoramide cyclic esters). Other suitable pharmaceutically acceptable ester-forming groups of hydroxyl groups include (1-10C) alkanoyl groups, such as acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups, (1-10C) alkoxycarbonyl groups, such as ethoxycarbonyl, N, N-(1-6C) 2 carbonyl, 2-dialkylaminoacetyl and 2-carboxyacetyl. Examples of ring substituents on phenylacetyl and benzoyl include aminomethyl, N-alkylaminomethyl, N,N-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl and 4-(1-4C)alkylpiperazin-1-ylmethyl. Suitable pharmaceutically acceptable ether-forming groups for hydroxy include α-acyloxyalkyl, such as acetoxymethyl and pivaloyloxymethyl.
[0165] Suitable pharmaceutically acceptable prodrugs of compounds of formula (I) or subformulas Ia to Ik having a carboxyl group are, for example, their in vivo cleavable amides, for example with amines such as ammonia, 1-4C alkylamines such as methylamine, [(1-4C) alkyl]2 amines such as dimethylamine, N-ethyl-N-methylamine or diethylamine, (1-4C) alkoxy-(2-4C) alkylamines such as 2-methoxyethylamine, phenyl-(1-4C) alkylamines such as benzylamine and amino acids such as glycine or their esters.
[0166] The suitable pharmaceutically acceptable prodrug of the compound of formula (I) or subformula Ia to Ik with amino group is, for example, its cleavable amide derivative in vivo. Suitable pharmaceutically acceptable amides from amino group include, for example, amides formed by (1-10C) alkanoyl groups, such as acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups. Examples of ring substituents on phenylacetyl and benzoyl groups include aminomethyl, N-alkylaminomethyl, N,N-dialkylaminomethyl, morpholinemethyl, piperazine-1-ylmethyl and 4-(1-4C) alkyl)piperazine-1-ylmethyl.
[0167] The in vivo effects of the compounds of formula (I) or the compounds of subformulas Ia to Ik may be exerted in part by one or more metabolites formed in the human or animal body after administration of the compounds of formula (I) or the compounds of subformulas Ia to Ik. As mentioned above, the in vivo effects of the compounds of formula (I) or subformulas Ia to Ik may also be exerted by the metabolism of precursor compounds (prodrugs).
[0168] Although the present invention may relate to any compound or specific group of compounds defined herein by way of optional, preferred or suitable features or in the form of a specific embodiment, the present invention may also relate to any compound or specific group of compounds explicitly excluding such optional, preferred or suitable features or specific embodiments.
[0169] Suitably, the present invention excludes any individual compound that does not possess the biological activity defined herein.
[0170] synthesis
[0171] The compounds of the present invention can be prepared by any suitable technique known in the art. Specific methods for preparing these compounds are further described in the accompanying examples.
[0172] In the descriptions of synthetic methods described herein and in any referenced synthetic methods for preparing starting materials, it is understood that all proposed reaction conditions, including the choice of solvents, reaction atmospheres, reaction temperatures, duration of experiments, and work-up procedures, can be selected by one skilled in the art.
[0173] Those skilled in the art of organic synthesis will appreciate that the functionality of the various parts of the molecule must be compatible with the reagents and reaction conditions used.
[0174] It should be understood that during the synthesis of the compounds of the invention in the methods defined herein, or during the synthesis of certain starting materials, it may be necessary to protect certain substituents to prevent them from undesirable reactions. A skilled chemist will understand when such protection is required and how to place such protecting groups in appropriate positions and then remove them.
[0175] For examples of protecting groups, see one of the many general texts on the subject, such as Protective Groups in Organic Synthesis by Theodora Green; (Publisher: John Wiley & Sons). Protecting groups may be removed by any convenient method described in the literature or known to the skilled chemist to be suitable for removal of the protecting group in question, such method being selected so as to effect removal of the protecting group with minimal disturbance of other groups in the molecule.
[0176] Thus, if reactants include groups such as amino, carboxyl or hydroxy, it may be necessary to protect this group in some of the reactions mentioned herein.
[0177] For example, the suitable protecting group of amino or alkylamino is for example acyl, for example alkanoyl such as acetyl, alkoxycarbonyl, for example methoxycarbonyl, ethoxycarbonyl or tert-butyloxycarbonyl, arylmethoxycarbonyl, for example benzyloxycarbonyl, or aroyl, for example benzoyl.The deprotection condition of the above-mentioned protecting group must change along with the selection of protecting group.Therefore, for example, acyl such as alkanoyl or alkoxycarbonyl or aroyl can be removed by for example hydrolysis with suitable alkali such as alkali metal hydroxide such as lithium hydroxide or sodium hydroxide.Or, acyl such as tert-butyloxycarbonyl can be removed for example by processing with suitable acid such as hydrochloric acid, sulfuric acid or phosphoric acid or trifluoroacetic acid, arylmethoxycarbonyl such as benzyloxycarbonyl can be removed for example by hydrogenation on catalyst such as palladium on carbon, or by processing with Lewis acid such as tri(trifluoroacetic acid boron).The suitable alternative protecting group of primary amino is for example phthaloyl, which can be removed by using alkylamine, for example dimethylaminopropylamine, or by processing with hydrazine.
[0178] The suitable protecting group of hydroxyl is for example acyl, for example alkanoyl such as acetyl, aroyl such as benzoyl, or arylmethyl such as benzyl. The deprotection conditions of the above-mentioned protecting group will inevitably change with the selection of protecting group. Therefore, for example, acyl such as alkanoyl or aroyl can be removed for example by hydrolysis with suitable alkali such as alkali metal hydroxide such as lithium hydroxide, sodium hydroxide or ammonia. Alternatively, arylmethyl such as benzyl can be removed by hydrogenation on a catalyst such as palladium on carbon.
[0179] A suitable protecting group for a carboxyl group is, for example, an esterifying group such as a methyl or ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or a tert-butyl group which may be removed, for example, by treatment with an acid such as an organic acid such as trifluoroacetic acid, or a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium on carbon.
[0180] Resins can also serve as protecting groups.
[0181] The method for synthesizing the compounds of formula (I) or sub-formulae Ia to Ik will vary depending on the nature of the variable groups A1, A2 or A3.
[0182] In a particular method of the invention, the method for synthesizing a compound of formula I comprises reacting a compound of formula A or B as shown below in the presence of a copper catalyst (e.g., Cu(OCOCF3)) and a suitable ligand (e.g., 1,10 phenanthroline):
[0183]
[0184] Among them A 1a or A 2a is a group CB, wherein B is boronic acid or a boronic acid ester (eg, boronic acid pinacol ester); and A1 and A2 are each as defined herein;
[0185] React with the following compound:
[0186] M[R1]
[0187] wherein M is a metal (eg, Na), and R1 is as defined above.
[0188] In one embodiment, the reacting comprises reacting a compound of formula A in a process as defined above.
[0189] Suitably, B is a borate ester (eg pinacol borate).
[0190] Suitably, M is Na, the copper catalyst is Cu(OCOCF3), and the ligand is 1,10 phenanthroline.
[0191] Suitably, R1 is 123 I.
[0192] Suitably, the reaction is carried out in a suitable solvent, for example a mixture of methanol and water.
[0193] Suitably, the reaction is carried out at an elevated temperature of 50 to 85°C (eg 80°C) for 10 to 120 minutes (eg 25 minutes).
[0194] The synthesis of compounds of formula Ij as defined herein is particularly challenging. In a particular method of the invention, the method of synthesizing a compound of formula Ij or a pharmaceutically acceptable salt thereof comprises reacting a compound of formula Aj as shown below in the presence of a copper catalyst (e.g., Cu(OCOCF3)) and a suitable ligand (e.g., 1,10 phenanthroline):
[0195]
[0196] wherein B is boronic acid or a boronic acid ester (eg, pinacol boronic acid ester); and A1 and A2 are each as defined herein; reacted with a compound of the formula:
[0197] M[ 123 I]
[0198] Wherein M is a metal (eg, Na).
[0199] Suitably, B is a borate ester (eg pinacol borate).
[0200] Suitably, M is Na, the copper catalyst is Cu(OCOCF3), and the ligand is 1,10 phenanthroline.
[0201] Suitably, the reaction is carried out in a suitable solvent, for example a mixture of methanol and water.
[0202] Suitably, the reaction is carried out at an elevated temperature of 50 to 85°C (eg 80°C) for 10 to 120 minutes (eg 25 minutes).
[0203] Once a compound of formula (I) or subformulas Ia to Ik has been synthesized by any of the methods defined herein, the method may further comprise the additional step of:
[0204] (i) removing any protecting groups present;
[0205] (ii) converting a compound of formula (I) into another compound of formula (I);
[0206] (iii) forming a pharmaceutically acceptable salt, hydrate or solvate thereof; and / or
[0207] (iv) forming a prodrug thereof.
[0208] An example of (ii) above is when a compound of formula (I) is synthesized, then one or more groups may be further reacted to change the nature of that group and provide an alternative compound of formula (I).
[0209] The resulting compounds of formula (I) or subformulas Ia to Ik may be isolated and purified using techniques well known in the art.
[0210] The compounds of formula (I) or sub-formulae Ia to Ik can be synthesized by the synthetic routes shown in the Examples section below.
[0211] Pharmaceutical composition
[0212] According to another aspect of the present invention, there is provided a pharmaceutical composition comprising the compound of the present invention as defined above or a pharmaceutically acceptable salt, hydrate or solvate thereof, and a pharmaceutically acceptable diluent or carrier.
[0213] The compositions of the invention may be in a form suitable for oral use (e.g. tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), in a form suitable for topical use (e.g. creams, ointments, gels or aqueous or oily solutions or suspensions), in a form suitable for administration by inhalation (e.g. finely divided powders or liquid aerosols), suitable for administration by insufflation (e.g. as finely divided powders) or suitable for parenteral administration (e.g. as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular, intraperitoneal or intramuscular administration, or as a suppository for rectal administration).
[0214] The compositions of the present invention can be obtained by conventional methods using conventional pharmaceutical excipients known in the art. Thus, compositions for oral administration may contain, for example, one or more coloring agents, sweeteners, flavoring agents and / or preservatives.
[0215] An effective amount of a compound of the invention for use in treatment is an amount sufficient to treat or prevent, slow the progression of, and / or alleviate the symptoms associated with a proliferative condition as referred to herein.
[0216] The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the individual treated and the particular route of administration.
[0217] use
[0218] Wherein R1 is selected from 123 I. 124 I. 131 I. 127 I or 211 The compounds of the invention of At are suitable for the following therapeutic uses and applications. In particular, wherein R1 is 123 The compounds of the invention of formula I are particularly effective therapeutic agents. In particular, in the examples described herein, the compounds of formula Ij have demonstrated excellent activity.
[0219] Where R1 is 124 The compounds of the present invention of I are suitable for PET imaging applications. PET imaging is well known in the art, wherein R1 is 124 The compounds of the invention of I are suitable agents for PET imaging of cancer, in particular cancers expressing the PARP enzyme.
[0220] Such compounds can be administered into the body and accumulate in cancer. The compositions for administering these compounds are the same as the pharmaceutical compositions defined herein. Similarly, the delivery routes of these compounds are the same as the therapeutic compounds defined herein.
[0221] Wherein R1 is 123The compounds of I are useful in therapeutic applications (as described above) and imaging applications. For example, such compounds can be used, for example, in dosimetry studies, patient selection and / or treatment tracking.
[0222] Therapeutic uses and applications
[0223] The compounds provided by the present invention are radiopharmaceuticals and are capable of releasing a lethal dose of radiation to tumor cells. Suitably, the compounds of the present invention suitable for therapeutic applications are those wherein R1 is 123 I. 131 I or 211 At, especially 123 I compound.
[0224] Therefore, the compounds of the present invention are useful in the treatment of cancer.
[0225] The compounds of the present invention are particularly useful for targeting cancers that express the PARP enzyme.
[0226] According to one aspect of the present invention there is provided a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition, for use in therapy.
[0227] According to another aspect of the present invention there is provided a compound as defined herein or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition for use as a medicament.
[0228] According to one aspect of the present invention, there is provided a method of treating cancer in a patient in need of such treatment, the method comprising administering to the patient a therapeutically effective amount of a compound as defined herein or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.
[0229] According to another aspect of the present invention, there is provided a compound as defined herein or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein for use in treating cancer.
[0230] According to another aspect of the present invention, there is provided use of a compound as defined herein or a pharmaceutically acceptable salt, hydrate or solvate thereof in the preparation of a medicament for treating cancer.
[0231] According to a specific aspect of the present invention, there is provided a method for treating cancer expressing the PARP enzyme in a patient in need of such treatment, the method comprising administering to the patient a therapeutically effective amount of a compound as defined herein or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein.
[0232] According to another specific aspect of the present invention, there is provided a compound as defined herein or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, for use in treating cancer expressing PARP enzyme.
[0233] According to another specific aspect of the present invention, there is provided use of a compound as defined herein or a pharmaceutically acceptable salt, hydrate or solvate thereof in the preparation of a medicament for treating cancer expressing the PARP enzyme.
[0234] The compounds of the invention can be used to treat any suitable cancer that is susceptible to treatment. Examples of cancers that can be targeted (e.g., adenoid cystic carcinoma, adrenal tumors, amyloidosis, anal cancer, appendix cancer, astrocytoma, ataxia-telangiectasia, Beckwith-Wiedemann syndrome, biliary cancer (cholangiocarcinoma), Birt-Hogg-Dubé syndrome, bladder cancer, bone cancer, brain stem glioma, brain tumor, breast cancer, Carney syndrome, central nervous system tumors, cervical cancer, colorectal cancer, Cowden syndrome, craniopharyngioma, desmoplastic infantile ganglioglioma, ependymoma, esophageal cancer, Ewing sarcoma, eye cancer, Eyelid cancer, familial adenomatous polyposis, familial GIST, familial malignant melanoma, familial non-VHL clear cell renal cell carcinoma, familial pancreatic cancer, gallbladder cancer, gastrointestinal stromal tumor-GIST, germ cell tumors, gestational trophoblastic disease, head and neck cancer, hereditary breast and ovarian cancer, hereditary diffuse gastric cancer, hereditary leiomyomatosis and renal cell carcinoma, hereditary mixed polyposis syndrome, hereditary pancreatitis, hereditary papillary renal cancer, juvenile polyposis syndrome, kidney cancer, lacrimal gland tumors, laryngeal and hypopharyngeal cancer, leukemia (acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), B cell Prolymphocytic leukemia, hairy cell leukemia, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), chronic T-cell lymphocytic leukemia, eosinophilic leukemia), Li-Fraumeni syndrome, liver cancer, lung cancer (non-small cell lung cancer, small cell lung cancer), lymphoma (Hodgkin, non-Hodgkin), Lynch syndrome, mastocytosis, medulloblastoma, melanoma, meningioma, mesothelioma, multiple endocrine neoplasia type 1 and type 2, multiple myeloma, MUTYH (or MYH)-associated polyposis, myelodysplastic syndrome (MDS), nasal and sinus cancer, nasal pharyngeal cancer, neuroblastoma, neuroendocrine tumors (e.g., of the gastrointestinal tract, lung, or pancreas), neurofibromatosis type 1 and type 2, nevoid basal cell carcinoma syndrome, oral cavity and oropharyngeal cancer, osteosarcoma, ovarian / fallopian tube / peritoneal cancer, pancreatic cancer, parathyroid cancer, penile cancer, Peutz-Jeghers syndrome, pheochromocytoma, paraganglioma, pituitary tumors, pleuropulmonary blastoma, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcomas (e.g., Kaposi's sarcoma or soft tissue), skin cancer, small intestine cancer, stomach cancer, testicular cancer, thymoma and thymic cancer, thyroid cancer, tuberous sclerosis, uterine cancer, vaginal cancer, Von Hippel-Lindau syndrome, vulvar cancer, Waldenstrom's macroglobulinemia, Werner syndrome, Wilms tumor, and xeroderma pigmentosum).Specific cancers of interest include hematological cancers, such as lymphomas (including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), Burkitt's lymphoma (BL), and angioimmunoblastic T-cell lymphoma (AITL)), leukemias (including acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML)), multiple myeloma, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, endometrial cancer, gastroesophageal cancer, neuroendocrine cancer, osteosarcoma, prostate cancer, pancreatic cancer, small intestine cancer, bladder cancer, rectal cancer, bile duct cancer, central nervous system cancer, thyroid cancer, head and neck cancer, esophageal cancer, and ovarian cancer.
[0235] The compounds of the present invention are particularly useful for treating cancers that express the PARP enzyme. Specific examples of cancers that express the PARP enzyme include gliomas, glioblastomas, thyroid cancer, lung cancer (e.g., NSCLC), esophageal cancer, head and neck cancer, tongue cancer, gastric cancer, liver cancer (e.g., HCC), neuroendocrine cancer, pancreatic cancer (e.g., PDAC), colon cancer, kidney cancer, prostate cancer, breast cancer (e.g., TNBC, ductal and invasive subtypes), endometrial cancer, cervical cancer, ovarian cancer, melanoma / skin cancer, and lymphoma.
[0236] dose
[0237] The compounds of the present invention suitable for therapeutic use can be administered at any suitable dose. For example, the compounds of the present invention can be administered at a dose of 0.1 MBq to 10 GBq / cycle in 1 to 10 separate treatment cycles. The treatment cycle typically includes a fixed treatment period (e.g., 1 to 7 days) followed by a cool-off period (e.g., 1 to 21 days) during which no treatment is performed.
[0238] In a specific embodiment, the compound of Formula Ij is administered at a dose of 0.1 MBq to 10 GBq / cycle over 1 to 10 treatment cycles.
[0239] Route of administration
[0240] The compounds of the invention, or pharmaceutical compositions comprising these compounds, may be administered to a subject by any convenient route of administration, whether systemically / peripherally or locally (ie, at the site of desired action).
[0241] Routes of administration include, but are not limited to, oral (e.g., by ingestion); buccal; sublingual; transdermal (including, for example, by patch, plaster, etc.); transmucosal (including, for example, by patch, plaster, etc.); intranasal (e.g., by nasal spray); ocular (e.g., by eye drops); pulmonary (e.g., by inhalation or insufflation therapy, e.g., through the mouth or nose, using, for example, an aerosol); rectal (e.g., by suppository or enema); vaginal (e.g., by vaginal suppository); parenteral, e.g., by injection, including intratumoral, subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcutaneous, intraarticular, subarachnoid, and intrasternal; by implantation of a reservoir or depot, e.g., subcutaneously or intramuscularly.
[0242] Combination therapy
[0243] The compounds of the present invention may be used as a monotherapy, or, in addition to the compounds of the present invention, may also include conventional surgery, additional conventional radiotherapy or chemotherapy. Such chemotherapy may include one or more of the following categories:
[0244] (i) Antiproliferative / antitumor drugs and combinations thereof for use in medical oncology, such as but not limited to alkylating agents (e.g.
[0245] cisplatin, oxaliplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, butylsulfonate, temozolomide, and nitrosoureas); antimetabolites (e.g., gemcitabine and antifolates, such as fluoropyrimidines, such as 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytarabine, and hydroxyurea); antitumor antibiotics (e.g., anthracyclines, such as adriamycin, bleomycin, doxorubicin, bicin), daunorubicin, epirubicin, idarubicin, mitomycin-C, dactinomycin, and mithramycin); antimitotic agents (e.g., vinca alkaloids, such as vincristine, vinblastine, vindesine, and vinorelbine, and taxanes, such as paclitaxel and docetaxel, and multikinase inhibitors); and topoisomerase inhibitors (e.g., epipodophyllotoxins, such as etoposide and teniposide, amsacrine, topotecan, and camptothecin);
[0246] (ii) Cytostatic agents, such as, but not limited to, antiestrogens (e.g., tamoxifen, fulvestrant, tolbutamide,
[0247] remifene, raloxifene, droloxifene, and iodophenoxyphene), antiandrogens (e.g., bicalutamide, flutamide, nilutamide, and cyproterone acetate), LHRH antagonists or LHRH agonists (e.g., goserelin, leuprolide, and buserelin), steroid hormones, including progestins (e.g., megestrol acetate) and corticosteroids (e.g., dexamethasone, prednisone, and prednisolone), aromatase inhibitors (e.g., anastrozole, letrozole, forazola, and exemestane), and 5-reductase inhibitors, such as finasteride;
[0248] (iii) anti-invasive agents, such as but not limited to the c-Src kinase family inhibitor 4-(6-chloro-2,3-methylenedioxyphenyl)
[0249] amine)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline (AZD0530;
[0250] International Patent Application WO 01 / 94341), N-(2-chloro-6-methylphenyl)-2-{6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-ylamino}thiazole-5-carboxamide (dasatinib, BMS-354825; J.Med.
[0251] Chem., 2004, 47 , 6658-6661), bosutinib (SKI-606), and metalloproteinase inhibitors such as marimastat, urokinase plasminogen activator receptor function inhibitors, or heparanase antibodies;
[0252] (iv) inhibitors of growth factor function, such as, but not limited to, growth factor antibodies and growth factor receptor antibodies (e.g., the anti-erbB2 antibody trastuzumab [Herceptin TM ], the anti-EGFR antibody panitumumab, the anti-erbB1 antibody cetuximab [Erbitux, C225] and any growth factor or growth factor receptor antibody disclosed by Stern et al. (Critical reviews in oncology / haematology, 2005, Vol.54, pp11-29); such inhibitors also include tyrosine kinase inhibitors, such as inhibitors of the epidermal growth factor family (e.g., EGFR family tyrosine kinase inhibitors, such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, ZD1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-N-
[0253] (3-Chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)-quinazolin-4-amine (CI 1033), erbB2 tyrosine kinase inhibitors such as lapatinib); inhibitors of the hepatocyte growth factor family; inhibitors of the insulin growth factor family; inhibitors of the platelet-derived growth factor family, such as imatinib and / or nilotinib (AMN107); inhibitors of serine / threonine kinases (e.g., Ras / Raf signaling inhibitors, such as farnesyl transferase inhibitors, such as sorafenib (BAY43-9006), tipifarnib (R115777) and lonafarnib (SCH66336)), inhibitors of cell signaling through MEK and / or AKT kinases, c-kit inhibitors, abl kinase inhibitors, PI3 kinase inhibitors, Plt3 kinase inhibitors, CSF-1R kinase inhibitors, IGF receptor (insulin-like growth factor) kinase inhibitors; Aurora kinase inhibitors and cyclin-dependent kinase inhibitors, such as CDK2 and / or CDK4 inhibitors;
[0254] (v) anti-angiogenic agents, such as, but not limited to, those that inhibit the action of vascular endothelial growth factor [e.g., the anti-vascular endothelial growth factor antibody bevacizumab (Avastin TM ) and, for example, VEGF receptor tyrosine kinase inhibitors, such as vandetanib (ZD6474), vatalanib (PTK787), sunitinib (SU11248), axitinib (AG-013736) and pazopanib (GW 786034).
[0255] (vi) vascular damaging agents, such as, but not limited to, Compretin A4 and compounds disclosed in International Patent Applications WO 99 / 02166, WO 00 / 40529, WO 00 / 41669, WO 01 / 92224, WO 02 / 04434 and WO 02 / 08213;
[0256] (vii) endothelin receptor antagonists, such as zilpotan (ZD4054) or atrasentan;
[0257] (viii) antisense therapies, such as, but not limited to, those directed against the targets listed above, e.g., ISIS2503, an anti-ras antisense;
[0258] (ix) immunotherapy, including, for example, cancer vaccines, antibodies, viruses (oncolytic viruses), and small molecule or cell therapies,
[0259] To increase the immunogenicity of the patient's tumor cells and / or promote cell-mediated anti-tumor responses. This therapy may include, but is not limited to, OX40 agonists, cGAS-STING agonists, A2a receptor antagonists, PI3 kinase inhibitors, TLR7 / 8 agonists, IDO inhibitors, arginase inhibitors, BTK inhibitors, and bromodomain inhibitors; transduction with microbial vectors of cancer antigens, direct transduction of cancer antigens into antigen-presenting cells, treatment with immune cells specific for cancer antigens (e.g., CAR-T), and treatment with antibodies, antibody fragments, and antibody-drug conjugates that enable the immune system to recognize tumor cells.
[0260] Such combination treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment.Such combination products employ the compounds of this invention within the dosage range described above and the other pharmaceutically active agent within its approved dosage range.
[0261] According to this aspect of the invention there is provided a combination for use in the treatment of cancer (eg cancer involving solid tumours) comprising a compound of the invention as defined above, or a pharmaceutically acceptable salt or solvate thereof, and another anti-tumour agent.
[0262] According to this aspect of the invention there is provided a combination for use in the treatment of a proliferative disease such as cancer (e.g. cancer involving solid tumours) comprising a compound of the invention as defined above or a pharmaceutically acceptable salt or solvate thereof, and any one of the anti-tumour agents listed above.
[0263] In another aspect of the present invention, there is provided a compound of the present invention or a pharmaceutically acceptable salt or solvate thereof for use in treating cancer in combination with another anti-tumor agent, the other anti-tumor agent being optionally selected from one listed above.
[0264] In this article, when the term "combination" is used, it should be understood to refer to simultaneous, separate or sequential administration. In one aspect of the invention, "combination" refers to simultaneous administration. In another aspect of the invention, "combination" refers to separate administration. In another aspect of the invention, "combination" refers to sequential administration. When administered sequentially or separately, delayed administration of the second component should not result in loss of the beneficial effects of the combination.
[0265] According to another aspect of the present invention, there is provided a pharmaceutical composition comprising a compound of the present invention or a pharmaceutically acceptable salt or solvate thereof, in combination with an anti-tumor agent (optionally selected from one listed above) and a pharmaceutically acceptable diluent or carrier.
[0266] Example - Part A BRIEF DESCRIPTION OF THE DRAWINGS
[0267] Figure 1:(A) Chemical structures of PARP inhibitors olaparib and CC1. (B) Enzyme inhibition of PARP1, 2 and 3 by CC1 and selection of known PARP inhibitors. (C) Heat map visualization of enzymatic activity screening of CC1 (10 mM) against 13 related enzymes. (D) [ 123 I] Radiosynthesis and structure of CC1. (E) AsPC1, PSN1 and U87MG cells were tested for [ 123 (F) Blockade of [I]CC1 uptake in AsPC1, PSN1, and U87MG cells by a panel of cold, unlabeled PARP, ALDH2, or IMPDH2 inhibitors. 123 I] CC1 uptake. Asterisks indicate significance levels: ns, P>0.05; *, P<0.05; **, P<0.01; ***, P<0.001; and ****, P<0.0001.
[0268] Figure 2 :(A,B) In AsPC1, PSN1 and U87MG, exposure to [ 123 I]CC1 (50 kBq, 20 GBq / μmol) for 1 hour and flow cytometric measurement of PARP1, 2 and 3 and γ-H2AX expression at 0, 1 or 24 hours. (C) Clonogenic assay comparing cells exposed to [ 123 I]CC1 or equivalent concentrations of CC1 or olaparib for 1 hour.
[0269] Figure 3 :(A) Intravenous injection 123 Representative dynamic SPECT images after administration of [I]CC1 (3 MBq, 20 GBq / μmol). The median time frame is expressed in minutes. Images are presented as maximum intensity projections. (B) VOI analysis of dynamic imaging. (C) Intravenous administration of [ 123 I]CC1 (3MBq, 20GBq / μmol) 1, 2, or 24 hours later, [ 123 I] Biodistribution of CC1 in selected tissues of mice bearing PSN1 xenografts.
[0270] Figure 4 :(A) Intravenous injection [ 123 Biodistribution of I]CC1 (3 MBq, Am = 20 GBq / μmol) (n = 3 / group) in selected tissues of PSN1 xenograft-bearing mice 2 hours after administration with or without excess cold, unlabeled rucaparib (0.5 mg). (B) shows 123 Autoradiographs of PSN1 tumor sections with I localization. Asterisks indicate significance levels: ns, P>0.05; *, P<0.05; **, P<0.01; ***, P<0.001; and ****, P<0.0001.
[0271] Figure 5 :(A) Single administration of CC1 or [ 123 I] Tumor growth after CC1 (3 MBq, 20 GBq / μmol). (B) Administration of CC1 or [ 123 I] Kaplan-Meier survival plot after CC1. (C) Administration of CC1 or [ 123 I] Animal body weight after CC1.
[0272] Supplementary drawings:
[0273] Supplementary Figure 1 : Catalytic inhibition of PARP1, 2, or 3 by increasing concentrations of CC1, olaparib, or rucaparib
[0274] Supplementary Figure 2 : Flow cytometric frequency histogram detection of PARP1, 2 and 3 and IMPDH2 expression in AsPC1, PSN1 and U87MG cells.
[0275] Supplementary Figure 3 :(A) ASPC1, PSN1 and U87MG cells [ 123 I] Time-dependent uptake of CC1. (B) [ 123 I] Cellular retention assay of CC1 in AsPC1, PSN1 and U87MG cells.
[0276] Supplementary Figure 4 : Flow cytometry measurements of exposure to [ 123 I] The expression of PARP1, 2 and 3 in cells after CC1. Figure 5 :Mice intravenously injected 123 I] VOI analysis of dynamic imaging after CC1.
[0277] Materials and methods
[0278] Synthesis and characterization of CC1
[0279] Unless otherwise stated, all reagents were purchased from Sigma-Aldrich and used without further purification. Olaparib, rucaparib, veliparib, talazoparib, and niraparib were purchased from Stratech Scientific Ltd (UK). Daidzein and mycophenolate mofetil were purchased from Cambridge Biosciences Ltd (UK) and Insight Biotechnology Ltd, respectively. CC1 (4-[(3-[(4-cyclopropylcarbonyl)piperazin-1-yl]carbonyl-4-iodophenyl]methyl(2H)phthalazin-1-one) (1) was synthesized by a modified literature method. For a full description of the protocol, see the Supplementary Information.
[0280] The catalytic activity of PARP-1, 2, and 3 was measured in vitro using a commercially available colorimetric assay (Trevigen, Gaithersburg, MD) in the presence of varying concentrations of established PARP inhibitors or CC1 according to the manufacturer's instructions. The ability of 10 nM CC1 to inhibit the catalytic activity of a range of PARP family enzymes was performed by AMS Biotech Europe Ltd. according to the BPS assay kit protocol.
[0281] [ 123 Radiosynthesis of I]CC1
[0282] sodium[ 123 I] Iodide solution in 0.1N sodium hydroxide (GE, UK). 123 I]CC1 was synthesized from appropriate boronic acid ester precursors by a modified procedure from (1,2) Figure 1 ). Radiochemical yields of >95% and molar activities of >20 GBq / μmol were routinely obtained. Activity yields were >75% (ndc) in a two-hour synthesis. For a complete description of the synthetic methods, see the Supplementary Information.
[0283] Cell culture
[0284] Human malignant glioma (U87MG) cells were generously donated by Professor Nicola Sibson of our institute and maintained in high glucose Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS, Gibco), 2mM L-glutamine, 100 units / mL penicillin and 0.1mg / mL streptomycin (Gibco). Pancreatic cancer (AsPC1 and PSN1) cells were purchased from ATCC (UK) and maintained at Roswell Park Memorial Institute (RPMI) supplemented with 10% fetal bovine serum (FBS, Gibco), 2mM L-glutamine, 100 units / mL penicillin and 0.1mg / mL streptomycin (Gibco). Cells were grown in a humidified atmosphere at 37°C and 5% CO2. Cells were harvested and passaged with trypsin-EDTA solution. Cells were used for no more than 25 passages after recovery from liquid nitrogen storage. All cells were authenticated by STR profiling and tested regularly for the presence of mycoplasma.
[0285] Expression of PARP protein in vitro
[0286] The relative expression of PARP isoforms in AsPC1, PSN1, and U87MG cells was determined by flow cytometry of live cells. AsPC1, PSN1, and U87MG cells were seeded in 96-well plates (1×10 5Cells / well). The cells were washed with FACS buffer (PBS, 2% FBS, 1 mM EDTA, 0.1% NaN3) by centrifugation at 500×g for 5 minutes. The Foxp3 / Transcription Factor Staining Buffer Set (eBioscience TM , USA). Intracellular staining was performed in permeabilization buffer at 4°C in the dark for 30 min using the following antibodies: AF 488-conjugated anti-PARP-1 (1:100; sc-80070), AF594-conjugated anti-PARP-2 (1:100; sc-393310) and AF488-conjugated anti-PARP-3 (1:100; sc-390771) from Santa Cruz Biotechnology Inc. (USA), AF 488-conjugated anti-IMPDH2 (1:500; ab-200770) from Abcam plc. (UK). Fixable vital dye ef780 (1:4000; eBioscience TM ; 65-0865-14) was used to distinguish live and dead cells. Immunostained cells were fixed with 10% formaldehyde for 15 minutes at room temperature. Flow cytometry was performed using a CytoFLEX flow cytometer (Beckman Coulter, USA) with appropriate lasers and filters, positive and negative controls. FlowJo TM The data were analyzed by RT-PCR (Tree Star Inc., BD Biosciences, USA).
[0287] [ 123 I]CC1 uptake and specificity in vitro
[0288] ASP C1 (1×10 5 cells / well), PSN1 cells (7.5×10 4 cells / well) or U87MG (1×10 5 Cells were seeded in 24-well plates containing growth medium (100 μM cells / well) and allowed to adhere for at least 20 hours. Cells were washed and exposed to cold, unlabeled PARP inhibitor (100 μM in a total of 270 μL growth medium) for 45 minutes at 37°C. 123 I]CC1, and the cells were incubated at 37°C for 45 minutes. The cell culture medium was removed and the cells were washed with PBS. The cells were lysed at room temperature for 15 minutes using RIPA buffer (950 mM Tris pH 8.0, 1% NP40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, and 150 mM sodium chloride), and the cell lysate was measured using an automated γ counter (PerkinElmer). 123The amount of I.
[0289] In a separate experiment, cells were prepared in a similar manner, but were washed and exposed to [ 123 I]CC1 different time intervals (1-120 minutes). Measure the cell lysate as above 123 The amount of I.
[0290] Cell retention assay Cells were seeded in 24-well plates as described above and allowed to adhere for at least 20 h. Cells were washed and exposed to 37 °C [ 123 I]CC1 for 30 minutes. Remove the cell culture medium, wash with PBS, and provide fresh medium (300 μL). Then incubate the cells further at 37°C. Remove the cell culture medium and wash the cells with PBS at different time points (0-24 hours). Lyse the cells using RIPA buffer (950 mM Tris pH 8.0, 1% NP40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, and 150 mM sodium chloride) at room temperature for 15 minutes, and measure the content of the cell lysate using an automated gamma counter (PerkinElmer). 123 The amount of I.
[0291] Colony formation assay Aliquots of cells (PSN1 and U87MG, 5000 cells) were exposed to increasing amounts of [ 123 I]CC1 (0-100 kBq) or cold, unlabeled olaparib or CC1 (0-0.1 mM in a total of 200 μL growth medium) for 60 min. Individual aliquots of cells were irradiated (0-10 Gy, using 137 Cs irradiator, 0.8 Gy / min). The cells were then washed and a portion of them were transferred to a 6-well plate containing 2 mL of growth medium and colony formation was measured two weeks after treatment. The number of colonies was normalized to the number of cells transferred to the plate to obtain the plating efficiency, which was then normalized to the plating efficiency of untreated cells.
[0292] [ 123 Quantification of nuclear protein expression after I]CC1 treatment
[0293] AsPC1, PSN1 or U87MG (1 × 10 6 Cells were seeded in 6-well plates (10 cells / well) and allowed to adhere for at least 20 hours. Cells were washed and exposed to [ 123I] CC1 (30 μL, 50 kBq, 20 GBq / μmol in 2 ml growth medium) for 1 hour. Cells were harvested using trypsin-EDTA solution, washed with FACS buffer (PBS, 2% FBS, 1 mM EDTA, 0.1% NaN3) and stained with Foxp3 / transcription factor staining buffer set (eBioscience TM , USA) for immunostaining. Intracellular staining was performed in permeabilization buffer at 4°C in the dark for 30 min, using the following antibodies: AF 488-conjugated anti-PARP-1 (1:100; sc-80070), AF 594-conjugated anti-PARP-2 (1:100; sc-393310) and AF488-conjugated anti-PARP-3 (1:100; sc-390771), from Santa Cruz Biotechnology (USA), AF 488-conjugated anti-IMPDH2 (1:500; ab-200770), from Abcam plc. (UK), γH2AX (1:1000; JBW301 Merck-Millipore). Fixable vital dye ef780 (1:4000; eBioscience TM ; 65-0865-14) for live / dead discrimination. Immunostained cells were fixed for 15 min at room temperature. Flow cytometry was performed using a CytoFLEX flow cytometer (Beckman Coulter, USA) with appropriate lasers and filters, positive and negative controls. FlowJo TM The data were analyzed by RT-PCR (Tree Star Inc., BD Biosciences, USA).
[0294] SPECT / CT imaging of immunocompromised mice bearing xenografts and 123 I] Biodistribution of CC1 Female Balb / c nu / nu (OlaHsd-Foxn1nu) mice, aged 4-6 weeks, were purchased from Envigo (UK). Animals were housed in IVC cages with a maximum of 6 per cage in an artificial day-night cycle facility. Food and water were provided ad libitum.
[0295] PSN1 cells were harvested using trypsin, washed twice with PBS, and resuspended in PBS: The cell suspension (PSN1: 2×10 6 Cells / 100 μL) were injected subcutaneously into the right front flank of mice and allowed to grow to approximately 200 mm 3 size.
[0296] Animals were administered [ 123 I]CC1 (3 MBq in 100 μL PBS, Am = 20 GBq / μmol). To evaluate the specificity of tumor uptake, an excess of unlabeled rucaparib (0.5 mg) was co-administered as a blocking agent. Animals were euthanized 60 or 120 minutes after injection of the radiolabeled compound. Selected organs, tissues and blood were removed and the percentage of injected dose per gram of tissue (% ID / g) was determined using a HIDEX automated gamma counter.
[0297] Using autoradiography performed on frozen tumor sections (10 μm), [ 123 I] Localization of CC1 in PSN1 xenografts. Uptake in PSN1 tumors was further compared with immunohistochemistry, PARP1, 2 and 3, and γ-H2AX staining. Full details of the procedures and protocols have been provided in the Supplementary Information.
[0298] The animals were administered 123 I]CC1, and dynamic PET images were acquired within 45 minutes. Images were analyzed using PMOD using a VOI-based analysis method.
[0299] In vivo treatment studies will be average tumor size of 82mm 3 PSN1 xenograft mice were randomly divided into groups and injected intravenously with [ 123 I]CC1 (3 MBq in 100 μL PBS, A m =20 GBq / μmol) or an equivalent amount of cold, unlabeled CC1. Mice and tumor size were monitored daily. Study endpoints were determined based on humane endpoints, including tumor size >1200 mm 3 , or weight loss > 15%.
[0300] Statistical analysis
[0301] All data were obtained at least three times. All statistical analyses and nonlinear regressions were performed using GraphPad Prism v6 or higher (GraphPad Software, San Diego, CA, USA). Data were tested for normality and analyzed appropriately by one-way or two-way analysis of variance (ANOVA). Unless otherwise stated, results are reported as mean ± one standard deviation.
[0302] result
[0303] CC1 is a selective and potent PARP inhibitor
[0304] CC1 was shown to be a potent PARP inhibitor with in-house determined cell-free IC50 values of 2.9 and 0.6 nM for PARP 1 and 2, respectively ( Figure 1 B. Supplement Figure 1 ). This compares favorably to olaparib (2.6 and 0.8 nM in the same assay). In contrast, CC1 (68 nM) inhibited PARP3 less than olaparib (18 nM). A single dose of CC1 (10 nM) was able to inhibit PARP1, PARP2, and PARP6 ( Figure 1 B), but to a lesser extent compared with olaparib, rucaparib, and other established PARP inhibitors. If interpreted as a proxy for PARP binding, CC1 binds PARP1, PARP2, and PARP3.
[0305] In vitro uptake 123 I]CC1
[0306] AsPC1, PSN1 and U87MG cells expressed PARP1, 2 and 3 to varying degrees, with PARP1 expression in AsPC1>U87MG>PSN1. 123 I]CC1 was taken up by all three cell lines within minutes and reached stability after 1 hour, whereas [ 123 I]CC1 is transiently retained in cells (Supplementary Appendix Figure 3 ). [ 123 I]CC1 was selectively taken up in AsPC1, PSN1 and U87MG cells, with the uptake amount being approximately 0.3 pmol / cell ( Figure 1 D). Addition of cold, unlabeled PARP inhibitor significantly reduced uptake, demonstrating selectivity for PARP ( Figure 1 E) [ 123 I]CC1 uptake was also reduced by the addition of daidzein and mycophenolate mofetil, two drugs that bind to other NAD + -binding enzymes ALDH2 and IMPDH2. Interestingly, all three cell types exposed to [ 123 I]CC1 leads to increased expression of PARP1 and PARP2 after 24 hours ( Figure 4 ). In addition, yH2AX expression (a marker of DNA double-strand breaks) was increased in mice exposed to [ 123 I] increased significantly 24 hours after CC1.
[0307] [ 123 I]CC1 reduces survival in colony formation assay
[0308] By exposure to relatively small amounts of [ 123I]CC1, from as little as 10 Bq of U87MG cells, the clonogenic survival of cells was significantly reduced. For PSN1 cells, [ 123 The IC50 value of CC1 was equivalent to 1 kBq / mL. Equal amounts of CC1 or olaparib had no effect.
[0309] [ 123 I] Biodistribution of CC1
[0310] Researched 123 Biodistribution of I]CC1 (3MBq, 20GBq / μmol) in PSN1 xenograft mice ( Figure 5 ). High absorption in the liver, gallbladder, large intestine / small intestine, showing similarity to [ 18 F] Olaparib has a similar hepatobiliary clearance pattern (1). Blood clearance showed a two-phase decay with fast and slow half-lives of 16.85 and 1.35 minutes, respectively, resulting in a weighted half-life of 1.86 minutes (CI95 1.64-2.09 minutes). Tumor uptake in PSN-1 xenografts reached 0.9±0.06% ID / g 1 hour after intravenous administration.
[0311] [ 123 I] Therapeutic effect of CC1 in PSN1 mouse model
[0312] The results were tested in mice bearing PSN1 xenografts. 123 I] CC1 for the treatment of tumors expressing the PARP enzyme. Compared with animals exposed to cold, unlabeled CC1, [ 123 A single intravenous administration of I]CC1 resulted in significant inhibition of tumor growth (p=0.04) without signs of severe toxicity as determined by the lack of weight loss in mice.
[0313] discuss
[0314] PARP inhibitors trap the PARP enzyme onto broken DNA. This close proximity to DNA makes PARP inhibitors good vehicles for carrying Auger electron-emitting radionuclides. These short-range electron-emitting radionuclides are significantly radiotoxic to cells if they decay close to DNA. Here we synthesized a compound that contains 123 I, an Auger electron emitter, which can bind PARP. Compounds of this type can be used therapeutically. Importantly, the very low concentrations that have allowed for radionuclide therapy do not lead to global catalytic inhibition of PARP enzyme activity. Instead, it is the Auger electron emission that causes DNA damage, leading to growth inhibition. We found that [ 123 I]CC1 specifically binds to the PARP enzyme and is active when exposed to only as little as 10 Bq (which is a very low amount) [123 I]CC1 significantly reduced the clonogenic survival of PARP-expressing cancer cells after one hour. Interestingly, because 123 In addition to being an Auger electron emitter, I also emits gamma rays, which allows gamma detector detection and SPECT imaging. We found that the required imaging [ 123 I]CC1 has been shown to effectively inhibit tumor growth in a mouse model of human tumor xenografts. However, other radiolabeled compounds, such as [ 18 F] Olaparib, can be used as a companion diagnostic. Specifically, [ 18 F] Olaparib can be used for PET imaging of PARP and as a companion diagnostic.
[0315] No gross toxicity in vivo was observed: Uptake of other radiolabeled PARP inhibitors in the liver, gallbladder and intestine, as well as in the kidneys, is thought to be intraluminal. The short path length of the Auger electrons ensures that DNA damage by the radiolabeled compounds in these tissues is very minimal.
[0316] Example - Part B BRIEF DESCRIPTION OF THE DRAWINGS
[0318] Figure 6 :Fig. CC1 in PSN1, AsPC1 or CAPAN1 cells blocks the expression of [ 123 I] CC1 uptake. Asterisks indicate statistical significance levels: *, P < 0.05.
[0319] Figure 7 : (E) In mice bearing PSN-1, U87MG, or MDA-MB-231 xenografts, [ 123 Autoradiographs of tumor sections harvested 2 h after administration of [I]CC1 (3 MBq). (F) In mice bearing PSN-1, U87MG, or MDA-MB-231 xenografts, intravenous injection of [ 123 I] Tumor uptake 2 hours after CC1 (3 MBq). Asterisks indicate significance levels: ns, P>0.05; *, P<0.05.
[0320] Figure 8 : (A, B) In mice bearing PSN-1 xenografts, a single intravenous administration of [ 123 Tumor growth and Kaplan-Meier survival plots after administration of [ 123 Representative photographs of mice bearing PSN-1 xenografts after CC1 or 15 days after CC1; (D) administration of [ 123I] Animal weights after CC1 or CC1. (E, F) In mice bearing U87MG or MDA-MB-231 xenografts, a single i.v. injection of [ 123 I]CC1 (3MBq) or an equal amount of unlabeled CC1 after tumor growth curve. (G) After administration of [ 123 Representative H&E staining in selected normal tissues 28 days after I]CC1 (3 MBq) or untreated C57 / Bl6 mice.
[0321] Supplementary drawings:
[0322] Supplementary Figure 6 : Western blot showing the expression of PARP1 and PARP2 in AsPC1, PSN-1 and U87MG whole cell lysates in vitro.
[0323] Supplementary Figure 7 :(A) ASP C1, PSN1 and U87MG cells [ 123 I] Time-dependent uptake of CC1. (B) After 1 h of exposure in AsPC1, PSN1 and U87MG cells, [ 123 I] Cell-associated retention of CC1. Figure 8 :Flow cytometry measurements showed that PSN1, AsPC1 and U87MG cells exposed to [ 123 I]CC1 (50 kBq, 18 GBq / μmol) was administered for 1 hour or 24 hours, and the number of cells with higher PARP2 expression increased. Supplementary Figure 9: Intravenous bolus administration of [ 123 VOI analysis of blood clearance after I]CC1 (3 MBq).
[0324] Materials and methods
[0325] Synthesis and characterization of CC1 and [ 123 I] Radiosynthesis of CC1 was performed as described in Part A above.
[0326] Cell culture
[0327] Human malignant glioma (U87MG) cells were generously donated by Professor Nicola Sibson at our institute and maintained in high glucose Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS, Gibco), 2mM L-glutamine, 100 units / mL penicillin and 0.1mg / mL streptomycin (Gibco). Pancreatic cancer (AsPC1, PSN1 and CAPAN-1) and breast cancer (MDA-MB-231) cells were purchased from ATCC (UK) and maintained at Roswell Park Memorial Institute (RPMI) supplemented with 10% fetal bovine serum (FBS, Gibco), 2mM L-glutamine, 100 units / mL penicillin and 0.1mg / mL streptomycin (Gibco). Cells were grown in a humidified atmosphere at 37°C and 5% CO2. Cells were harvested and passaged with trypsin-EDTA solution. Cells were used for no more than 20 passages after recovery from liquid nitrogen storage. All cells were authenticated by the supplier and by STR profiling and were routinely tested for the presence of mycoplasma.
[0328] Expression of PARP protein in vitro
[0329] The relative expression of PARP1, 2, and 3 was determined by flow cytometry of live cells as described above in Section A. In an independent study, DNA double-strand break damage was quantified using an anti-γH2AX antibody (JBW301, 1:800) in combination with an AF488-conjugated anti-mouse antibody (Santa Cruz Biotechnology). The fixable vital dye EF 780 (1:4000; eBioscience TM 65-0865-14) was used to distinguish live cells from dead cells. Foxp3 transcription factor staining buffer set (eBioscience TM Immunostained cells were fixed at room temperature for 15 min (00-5523-00). Flow cytometry was performed using a CytoFLEX flow cytometer (Beckman Coulter, USA) with appropriate lasers and filters, positive and negative controls. TM The data were analyzed by RT-PCR (Tree Star Inc., BD Biosciences, USA).
[0330] [ 123 I]CC1 uptake and specificity in vitro
[0331] As described in Part A above, ASP C1 (1×10 5 cells / well), PS n1 (7.5×10 4cells / well) or U87MG (1×10 5 CAPAN-1 cells (7.5×10 4 In a separate experiment, cells were exposed to [ 123 I]CC1 for 30 min, washed, supplied with fresh growth medium, and cell-associated 123 The amount of I.
[0332] Colony Formation Assays Colony formation assays were performed on aliquots of PSN1, U87MG and MDA-MB-231 cells following the protocol outlined in Section A above.
[0333] [ 123 Quantification of nuclear protein expression after I]CC1 treatment
[0334] AsPC1, PSN1, or U87MG cells were quantified following the protocol outlined above in Section A. Relative expression of PARP1 and 2 was measured using flow cytometry. γH2AX expression, as a measure of DNA double-strand break damage, was assessed in a similar manner.
[0335] SPECT / CT imaging of immunocompromised mice bearing xenografts and 123 I] Biodistribution of CC1 Following the protocol described in Section A above, PSN1, U87MG, or MDA-MB-231 cells were harvested using trypsin, washed twice with PBS, and incubated in PBS: The cells were reconstituted in a high concentration matrix (1:1). The cell suspension was injected subcutaneously on the right posterior flank to allow tumor formation. When the tumor reached 100-200 mm 3 Animals were given [ 123 I]CC1 (3 MBq in 100 μL PBS, A m =124.3 GBq / μmol). To assess the specificity of tumor uptake, an excess of unlabeled rucaparib (0.5 mg) was co-administered as a blocking agent in some animals. Animals were euthanized 60 or 120 minutes after injection of the radiolabeled compound (n=3 per group). Selected organs, tissues, and blood were removed and the percentage of injected activity per gram of tissue (%IA / g) was determined using a HIDEX automated gamma counter.
[0336] In a selected number of animals (n = 3), animals were anesthetized with 2% isoflurane and dynamic SPECT / CT imaging was performed for 1 hour using a MILabs VECTor4 camera equipped with an ultra-high resolution rat / mouse collimator (1.8 mm), followed by a cone-beam CT scan (55 kV, 0.19 mA) for anatomical reference and attenuation correction. During image acquisition, anesthesia was maintained using 2.5% isoflurane. SPECT images were reconstructed using U-SPECT-Rec3.22 software (MILabs, Utrecht, the Netherlands), applying a pixel-based algorithm, ordered subset expectation maximization (OSEM), for iodine-123 (energy window setting 141.3-172.7 keV), using 4 subsets, 4 iterations and a voxel size of 0.6 mm. Reconstructed SPECT and CT images were viewed and analyzed using PMOD v.3.37 (PMOD Technologies, Zurich, Switzerland).
[0337] [ 123 The localization of I]CC1 in PSN1 xenografts was further determined ex vivo using autoradiography performed on frozen tumor sections (10 μm). The uptake in tumor tissues was further compared with immunohistochemistry (staining for PARP1 and 2).
[0338] toxicology
[0339] After intravenous injection of 3 MBq [ 123 H&E staining was performed on selected tissues 24 hours and 28 days after CC1 to untreated C57 / Bl6 mice (n=3 per time point). Liver, spleen, kidney and intestine were studied by an experienced veterinary pathologist and compared with age-matched untreated control animals.
[0340] Tissues were further stained for γH2AX to investigate DNA double-strand break damage, and livers were additionally stained for PAS as a marker of glycogen storage.
[0341] In vivo treatment studies will be average tumor size of 82mm 3 PSN1 xenograft mice were randomly divided into groups and injected intravenously with [ 123 I]CC1 (3 MBq in 100 μL PBS, A m =124-342 GBq / μmol) or an equivalent amount of unlabeled CC1. Mice were monitored daily. Tumor size was measured with a caliper. Study endpoints were based on humane endpoints, including tumor size >1000 mm 3 , or weight loss > 15%.
[0342] Dosimetry
[0343] In vitro, radiation absorbed dose was determined using uptake and retention data in U87MG cells using the MIRD Cell Kit. The dimensions of the cells and nuclei were approximated as concentric circles, with sizes based on confocal microscopy (14 μm cell diameter, 8 μm nucleus diameter).
[0344] Statistical analysis
[0345] All data were obtained at least three times. All statistical analyses and nonlinear regressions were performed using GraphPad Prism v8 or higher (GraphPad Software, San Diego, CA, USA). Data were tested for normality and analyzed as appropriate by one-way or two-way analysis of variance (ANOVA). Unless otherwise stated, results are reported as mean ± one standard deviation.
[0346] result
[0347] In vitro cells 123 I]CC1 uptake is PARP selective 123 I]CC1 was reliably produced in good radiochemical yield with high A m ( Figure 1 D). AsPC1, PSN1, and U87MG cells expressed PARP1 and 2 to different extents, with PARP1 expression in AsPC1>U87MG>PSN1 (Supplementary Appendix Figure 6 ). [ 123 I]CC1 was taken up by all three cell lines within minutes and reached a stable level after 1 hour (Supplementary Appendix). Figure 7 A). 123 I]CC1 is transiently retained in cells (Supplementary Appendix Figure 7 B) 123 I]CC1 was selectively taken up in AsPC1, PSN1 and U87MG cells, with the uptake amount being approximately 0.3 fmol / cell ( Figure 1 E, 1F, and 6). Addition of structurally related and unrelated non-tagged PARP inhibitors significantly reduced [ 123 I]CC1 cell-related amount (P < 0.0001), indicating that [ 123 I] PARP selective binding of CC1 ( Figure 6 ).
[0348] [ 123 I]CC1 induces DNA damage and reduces colony formation survival
[0349] γH2AX expression, a marker of DNA double-strand breaks, was observed in PSN-1 and U87MG cells exposed to low levels of [ 123I]CC1 (50 kBq) increased significantly within 24 hours after 1 hour ( Figure 2 B) All three cell types were exposed to [ 123 I]CC1 caused an increase in the expression of PARP1 and PARP2 within 24 hours after 1 hour of exposure ( Figure 2 A and Supplement Figure 8 ). Based on the absorption and retention values (supplemented with Figure 7 ), the in vitro cellular dose calculated by MIRDcell estimated the radiation absorbed dose (over 24 h) to be 7.89 Gy.
[0350] By exposure to relatively small amounts of [ 123 I]CC1, from as little as 10 Bq (20 MBq / μmol) of U87MG cells, significantly reduced the clonogenic survival of cells. 123 The IC50 value of CC1 is equivalent to 631 ± 35 Bq (in 200 μl). The efficacy against PSN1 cells in vitro is far less obvious. Equal amounts of CC1 or olaparib have no effect on the survival rate of clonogenicity ( Figure 1 E and 1F).
[0351] [ 123 I] The biodistribution of CC1 shows a hepatobiliary clearance pattern
[0352] In PSN1 xenograft mice, 123 Dynamic SPECT / CT imaging and biodistribution of I]CC1 (3 MBq, 20 GBq / μmol) Figure 3 , 4 , 7 and supplement Figure 5 and 9). High absorption in the liver and intestine suggests a hepatobiliary clearance pattern, similar to other radiolabeled PARP inhibitors ( Figure 3 A and B). Blood clearance showed a two-stage decay with fast and slow half-lives of 16.85 min and 1.35 min, respectively, resulting in a weighted half-life of 1.86 min (CI95 1.64-2.09 min) (Supplementary Fig. 9B). Cleavage counting biodistribution studies showed that tumor uptake in PSN-1 xenografts was 0.9 ± 0.06% IA / g 1 hour after intravenous administration, and normal tissue uptake was consistent with dynamic SPECT imaging ( Figure 3 C). After 24 hours, 0.033±0.017% IA / g 123 I]CC1 remained in the tumor 24 hours after injection. Co-administration of excess rucaparib to block the NAD+ binding pocket in the PARP enzyme significantly reduced tumor uptake (P<0.05) ( Figure 4 A), which was confirmed by autoradiography ( Figure 7 E). Tumor uptake was significantly lower in U87MG and MDA-MB-231 xenografts compared to PSN-1 xenografts (0.46 ± 0.01% IA / g for U87MG and 0.19 ± 0.01% IA / g for MDA-MB-231 xenografts) ( Figure 7 E and 7F).
[0353] [ 123 I]CC1 shows limited normal tissue toxicity
[0354] In order to 123 I]CC1 is used in radionuclide therapy of tumors, and whether the radiolabeled compound induces any toxicity in normal tissues was evaluated. Based on its biodistribution pattern, exposure to [ 123 I]CC1 causes radiation-induced damage to the liver and intestine. The kidneys were also evaluated due to partial renal clearance, given that radiolabeled PARP inhibitors [ 18 F] Olaparib's ability to bind specifically to spleen tissue also considered the spleen ( Figure 8 ).
[0355] Intravenous injection 123 The intestines of mice treated with I]CC1 (3 MBq) showed minimal infiltrates of lymphocytes and plasma cells. Scattered intact eosinophils were present within the lamina propria, but none of the mice showed signs of enterocyte necrosis or necrosis, and the apical brush border remained intact. Mitotic figures were regular and within normal counts. Observations 24 hours or 28 days after administration were no different. The kidneys showed no observable changes, while in the spleen, mild to moderate numbers of hemosiderin-laden phagocytes were observed at 24 hours and 28 days after administration. No signs of necrosis were seen.
[0356] In the liver, hepatocyte nuclei were centrally located and showed no signs of necrosis. Some small extramedullary hematopoiesis was present. Mild anisocytosis and anisokaryosis were seen. A few single scattered hepatocytes (0.1-0.2 per field) showed a shrunken shape, eosinophilic cytoplasm, and shrunken nuclei with condensed chromatin interpreted as pyknosis. A notable effect in the liver was diffuse cytoplasmic pallor / sparseness caused by macroscopic empty pinnate spaces and vacuoles with some residual flocculent granular cytoplasmic material, usually at the margins. Following administration of [ 123 I] The effect was slightly more pronounced in animals 28 days after CC1, although not statistically significant.
[0357] [ 123 Effective tumor growth inhibition of CC1 in PDAC xenograft tumor mice by intravenous injection of relatively small amounts of [ 123I]CC1 (3 MBq) showed significant tumor growth delay in mice bearing PSN1 xenografts ( Figure 8 Compared with animals exposed to cold, unlabeled CC1, [ 123 A single intravenous administration of [I]CC1 resulted in significant inhibition of tumor growth (p = 0.04) without signs of severe toxicity as determined by the lack of reduction in mouse body weight (p>0.05). U87MG xenografts responded less well than PSN-1 xenografts (p>0.05), whereas growth of MDA-MB-231 xenografts was not affected by the same amount of [ 123 I]CC1 effect (p>0.05).
[0358] discuss[ 123 I]CC1 has been shown to selectively bind PARP, causing DNA double-strand breaks and reducing clonogenic survival in vitro and tumor growth in vivo. 123 I-CC1 also induced increased expression of PARP1 and PARP2 in tumor tissue. Although this could form the basis for a possible feedback mechanism with multiple administrations, this was not investigated because single administration 123 I-CC1 (3 MBq) was therapeutically effective in PSN-1 xenograft-bearing mice. Although the efficacy in PSN1 cells in vitro was not as significant as the in vitro response in U87MG cells, the in vivo uptake in PSN1 tumors was higher than that in U87MG tumor xenografts, resulting in better therapeutic efficacy. This may be due to 123 Higher uptake of I results in higher absorbed radiation doses, different radiation sensitivities in vitro versus in vivo, and / or differences in growth rates and repopulation in vitro versus in vivo.
[0359] and 123 I-MAPi, 123 / 125 I-KX1, 125 I-KX-02-019, 211 At-MM4, 125 I-PARP-01 and 77 Compared with Br-GD1, [ 123I]CC1 has shown efficacy after a single intravenous administration at relatively low doses. Previous work has shown that small changes in the structure of PARP inhibitors can cause major changes in their properties. Factors that affect the efficacy of radioligand therapy with radiolabeled PARP inhibitors may include binding affinity, binding spectrum, bioavailability, pharmacokinetics, and tumor uptake. In addition, the capture of PARP enzymes by PARP inhibitors and the capture of PARP enzymes by radiolabeled PARP inhibitors may play an important role in their efficacy. Therefore, it can be expected that different radiolabeled PARP inhibitors may have very different therapeutic indices.
[0360] Many studies on radiolabeled PARP inhibitors have incorporated Auger electron emitters because the trapping of the PARP enzyme brings the PARP inhibitor into close proximity with the DNA, which is a good match for the short-range Auger electron emitters. 125 I is a very efficient Auger electron emitter, emitting about 23 low-energy electrons per decay, but considering the half-life, it is preferred to use 123 I. 123 I has 14 AEs per decay, a more manageable half-life, and has the advantage of being globally available.
[0361] Normal tissue toxicity was minimal. 123 The very short AE range of I may account for the lack of normal tissue toxicity: despite high uptake in the gallbladder, intestine, and bladder, the radiation dose from Auger electron emission would be very small due to the luminal uptake of the PARP inhibitor in these organs. In the liver, uptake of another labeled PARP inhibitor was shown to be cytoplasmic rather than nuclear. Assuming that an Auger electron emitter that decays in the cytoplasm is 30-fold less cytotoxic than one that decays in the nucleus, the uptake in the liver [ 123 The cytotoxicity of cytoplasmic uptake of I]CC1 will be much lower.
[0362] It has been shown that tumor tissue 18 The uptake of F-labeled olaparib is highly dependent on the administered mass and molar activity. 123 The same is true for I-CC1 and other PARP inhibitor-based radioligand therapies.
[0363] 123 I's gamma radiation also makes it an imaging agent. 123 I]CC1 can be considered a true diagnostic agent, with lower administered doses used for SPECT imaging and larger doses used for therapy. Alternatively, 18 F-(6) even 124I-labeled variants can be used to measure the relative expression of target enzymes in tumor tissues by PET imaging. 123 I]CC1 is a promising therapeutic radiopharmaceutical based on Auger electron emission PARP inhibitor.
Claims
1. A compound of formula I or a pharmaceutically acceptable salt or solvate thereof: in: A1 and A2 are independently selected from CR1 and CH, CR1 and CF, CR1 and N, CH and CR1, CF and CR1 or NH and CR1; R1 is a radioactive isotope of iodine (I) or astatine (At); A3 is selected from N-X1-R3 or C(R4)OR5; X1 is absent or selected from -C(O)-, -[CH2] 1-3 -, -C(O)NH-, -C(O)O- or -S(O) 0-2 -; R3 is H, (1-10C) alkyl, (3-8C) cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein each alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl is optionally replaced by one or more R A Substituent substitution; R4 is selected from H or C 1-4 Alkyl; and R5 is selected from (1-7C) alkyl, (3-8C) cycloalkyl, heterocyclic and aryl, which groups are optionally replaced by one or more R A Substituent substitution; Or R4 and R5 together with the carbon atom and oxygen atom to which they are attached form a spiro-C 5-7 Oxygen-containing heterocyclic group, which is optionally substituted by one or more R A The substituents are substituted or fused to the phenyl or 5- or 6-membered heteroaryl ring; and Each R A The substituents are independently selected from fluorine, cyano, (1-4C) alkyl, (1-4C) haloalkyl, (1-4C) hydroxyalkyl, phenyl, 4- to 6-membered heterocyclyl, 5- to 6-membered heteroaryl, -OR 1a 、-NR 1a R 1b 、-C(O)R 1a 、-C(O)N(R 1b )R 1a 、N(R 1b )C(O)R 1a 、-S(O) p R 1a (where p is 0, 1 or 2), -SO2N(R 1b )R 1a 、-N(R 1b )SO2R 1a , where R 1a and R 1b Each is independently selected from hydrogen, (1-4C)alkyl or (3-6C)alkyl.
2. The compound according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein: (i) A1 is CR1, and A2 is selected from CH, CF or N; or (ii) A1 is selected from CH, CF and N, and A2 is CR1.
3. The compound according to claim 2, or a pharmaceutically acceptable salt or solvate thereof, wherein A1 is CR1, and A2 is CH.
4. A compound according to any one of claims 1 to 3 or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is selected from 123 I. 131 I. 127 I or 124 I is a radioactive isotope of iodine (I) or a radioactive isotope of astatine (At) 211 At.
5. The compound according to claim 1 or claim 2, or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is selected from 123 I. 124 I or 131 I is a radioactive isotope of iodine (I).
6. The compound according to claim 1 or claim 3, or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is 123 I.
7. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein A3 is N-R3.
8. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein R3 is (1-6C)alkyl, (3-6C)cycloalkyl, phenyl, 4- to 6-membered heterocyclyl, or 5- to 6-membered heteroaryl, each of which is optionally substituted by one or more R A Substituent substitution.
9. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein R3 is (1-6C)alkyl or (3-6C)cycloalkyl, each of which is optionally substituted by one or more R A Substituent substitution.
10. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein R3 is (1-6C)alkyl or (3-6C)cycloalkyl.
11. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein R3 is (3-6C)cycloalkyl.
12. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein R3 is cyclopropyl.
13. The compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt or solvate thereof, wherein A3 is C(R4)OR5.
14. The compound according to claim 13 or a pharmaceutically acceptable salt or solvate thereof, wherein R4 is selected from H, C 1-4 alkyl, and R5 is selected from (1-7C)alkyl, 4 to 6 membered heterocyclyl and phenyl, said group being optionally substituted by one or more R A Substituent substitution.
15. The compound according to claim 13, or a pharmaceutically acceptable salt or solvate thereof, wherein R4 is selected from H, and R5 is (1-4C)alkyl.
16. The compound according to claim 13, or a pharmaceutically acceptable salt or solvate thereof, wherein R4 is selected from H, and R5 is methyl.
17. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein R A Selected from: (i) fluorine, cyano, (1-4C) alkyl, (1-4C) haloalkyl, (1-4C) hydroxyalkyl, phenyl, 4- to 6-membered heterocyclic group, 5- to 6-membered heteroaryl, -OR 1a 、-NR 1a R 1b 、-C(O)R 1a 、-C(O)N(R 1b )R 1a 、N(R 1b )C(O)R 1a 、-S(O) p R 1a (where p is 0, 1 or 2), -SO2N(R 1b )R 1a 、-N(R 1b )SO2R 1a , where R 1a and R 1b are each independently selected from hydrogen or (1-4C)alkyl; or (ii) fluorine, cyano, (1-4C) alkyl, (1-4C) haloalkyl, (1-4C) hydroxyalkyl, -OR 1a 、-NR 1a R 1b 、-C(O)R 1a 、-C(O)N(R 1b )R 1a 、N(R 1b )C(O)R 1a 、-S(O) p R 1a (where p is 0, 1 or 2), -SO2N(R 1b )R 1a 、-N(R 1b )SO2R 1a , where R 1a and R 1b Each is independently selected from hydrogen or (1-4C)alkyl.
18. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein the compound is a compound of Formula Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij or Ik as shown below: in, As the case may be: R1 is as defined in any one of claims 1 or 4-6; R3 is as defined in any one of the preceding claims; and R5 is as defined in any one of the preceding claims.
19. The compound according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein the compound is a compound of the formula:
20. A pharmaceutical composition comprising a compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.
21. A compound according to any one of claims 1 to 19, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition according to claim 20, for use in therapy.
22. The compound according to any one of claims 1 to 19, or a pharmaceutically acceptable salt or solvate thereof, or the pharmaceutical composition according to claim 20, for use in treating cancer.
23. The compound for treating cancer according to claim 20, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition thereof, wherein the cancer is a PARP-expressing cancer.
24. A compound for treating cancer according to claim 22 or claim 23, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition thereof, wherein the cancer is selected from glioma, glioblastoma, thyroid cancer, lung cancer (e.g., NSCLC), esophageal cancer, head and neck cancer, tongue cancer, gastric cancer, liver cancer (e.g., HCC), neuroendocrine cancer, pancreatic cancer (e.g., PDAC), colon cancer, kidney cancer, prostate cancer, breast cancer (e.g., TNBC, ductal and invasive subtypes), endometrial cancer, cervical cancer, ovarian cancer, melanoma / skin cancer, and lymphoma.
25. A method for treating cancer, comprising administering a therapeutically effective amount of a compound according to any one of claims 1 to 19 or a pharmaceutically acceptable salt or solvate thereof, or administering a pharmaceutical composition according to claim 20.
